<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction - Pang, R - 2021 | Cochrane Library</title> <meta content="Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction - Pang, R - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012336.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction - Pang, R - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012336.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012336.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction" name="citation_title"/> <meta content="Ran Pang" name="citation_author"/> <meta content="Guang An Men Hospital, China Academy of Chinese Medical Sciences" name="citation_author_institution"/> <meta content="pangran2002@gmail.com" name="citation_author_email"/> <meta content="Xin-Yao Zhou" name="citation_author"/> <meta content="Guang An Men Hospital, China Academy of Chinese Medical Sciences" name="citation_author_institution"/> <meta content="Xiangling Wang" name="citation_author"/> <meta content="Mayo Clinic" name="citation_author_institution"/> <meta content="Bin Wang" name="citation_author"/> <meta content="China Academy of Chinese Medical Sciences" name="citation_author_institution"/> <meta content="Xue-Lai Yin" name="citation_author"/> <meta content="Guang An Men Hospital, China Academy of Chinese Medical Sciences" name="citation_author_institution"/> <meta content="Hai Bo" name="citation_author"/> <meta content="Guang An Men Hospital, China Academy of Chinese Medical Sciences" name="citation_author_institution"/> <meta content="Jae Hung Jung" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD012336.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/02/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012336.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012336.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012336.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic alpha-Antagonists [adverse effects, *therapeutic use]; Bias; Cholinergic Antagonists [adverse effects, *therapeutic use]; Drug Therapy, Combination [adverse effects, methods]; Lower Urinary Tract Symptoms [*drug therapy, etiology]; Prostatic Hyperplasia [*complications]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012336.pub2&amp;doi=10.1002/14651858.CD012336.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="qy4lqFNF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012336\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012336\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","th","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012336.pub2",title:"Anticholinergics combined with alpha\\u2010blockers for treating lower urinary tract symptoms related to benign prostatic obstruction",firstPublishedDate:"Feb 10, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012336.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012336.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012336.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012336.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012336.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012336.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012336.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012336.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012336.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012336.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2654 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012336.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-sec-0107"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-sec-0098"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/appendices#CD012336-sec-0112"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/supinfo/CD012336StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/supinfo/CD012336StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information#CD012336-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ran Pang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information#CD012336-cr-0005">Xin-Yao Zhou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information#CD012336-cr-0006">Xiangling Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information#CD012336-cr-0007">Bin Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information#CD012336-cr-0008">Xue-Lai Yin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information#CD012336-cr-0009">Hai Bo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information#CD012336-cr-0010">Jae Hung Jung</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information/en#CD012336-sec-0126">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 February 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012336.pub2">https://doi.org/10.1002/14651858.CD012336.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012336-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012336-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012336-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012336-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012336-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012336-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD012336-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012336-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012336-abs-0001" lang="en"> <section id="CD012336-sec-0001"> <h3 class="title" id="CD012336-sec-0001">Background</h3> <p>Lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO) represent one of the most common clinical complaints in men. Alpha‐blockers are widely used as first‐line therapy for men with LUTS secondary to BPO, but up to one third of men report no improvement in their LUTS after taking alpha‐blockers. Anticholinergics used in addition to alpha‐blockers may help improve symptoms but it is uncertain how effective they are.  </p> </section> <section id="CD012336-sec-0002"> <h3 class="title" id="CD012336-sec-0002">Objectives</h3> <p>To assess the effects of combination therapy with anticholinergics and alpha‐blockers in men with LUTS related to BPO. </p> </section> <section id="CD012336-sec-0003"> <h3 class="title" id="CD012336-sec-0003">Search methods</h3> <p>We performed a comprehensive search of medical literature, including the Cochrane Library, MEDLINE, Embase, and trials registries, with no restrictions on the language of publication or publication status. The date of the latest search was 7 August 2020. </p> </section> <section id="CD012336-sec-0004"> <h3 class="title" id="CD012336-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials. Inclusion criteria were men with LUTS secondary to BPO, ages 40 years or older, and a total International Prostate Symptom Score of 8 or greater. We excluded trials of men with a known neurogenic bladder due to spinal cord injury, multiple sclerosis, or central nervous system disease, and those examining medical therapy for men who were treated with surgery for BPO. We performed three comparisons: combination therapy versus placebo, combination therapy versus alpha‐blockers monotherapy, and combination therapy versus anticholinergics monotherapy. </p> </section> <section id="CD012336-sec-0005"> <h3 class="title" id="CD012336-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the literature, extracted data, and assessed risk of bias. We performed statistical analyses using a random‐effects model and interpreted data according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. We used the GRADE approach to rate the certainty of evidence. </p> </section> <section id="CD012336-sec-0006"> <h3 class="title" id="CD012336-sec-0006">Main results</h3> <p>We included 23 studies with 6285 randomized men across three comparisons. The mean age of participants ranged from 54.4 years to 73.9 years (overall mean age 65.7 years). Of the included studies, 12 were conducted with a single‐center setting, while 11 used a multi‐center setting. We only found short‐term effect (12 weeks to 12 months) of combination therapy based on available evidence. </p> <p><b>Combination therapy versus placebo:</b> based on five studies with 2369 randomized participants, combination therapy may result in little or no difference in urologic symptom scores (mean difference (MD) –2.73, 95% confidence interval (CI) –5.55 to 0.08; low‐certainty evidence). We are very uncertain about the effect of combination therapy on quality of life (QoL) (MD –0.97, 95% CI –2.11 to 0.16; very low‐certainty evidence). Combination therapy likely increases adverse events (risk ratio (RR) 1.24, 95% CI 1.04 to 1.47; moderate‐certainty evidence); based on 252 adverse events per 1000 participants in the placebo group, this corresponds to 61 more adverse events (95% CI 10 more  to 119 more) per 1000 participants treated with combination therapy. </p> <p><b>Combination therapy versus alpha‐blockers alone:</b> based on 22 studies with 4904 randomized participants, we are very uncertain about the effect of combination therapy on urologic symptom scores (MD –2.04, 95% CI –3.56 to –0.52; very low‐certainty evidence) and QoL (MD –0.71, 95% CI –1.03 to –0.38; very low‐certainty evidence). Combination therapy may result in little or no difference in adverse events rate (RR 1.10, 95% CI 0.90 to 1.34; low‐certainty evidence); based on 228 adverse events per 1000 participants in the alpha‐blocker group, this corresponds to 23 more adverse events (95% CI 23 fewer to 78 more) per 1000 participants treated with combination therapy. </p> <p><b>Combination therapy compared to anticholinergics alone:</b> based on three studies with 1218 randomized participants, we are very uncertain about the effect of combination therapy on urologic symptom scores (MD –3.71, 95% CI –9.41 to 1.98; very low‐certainty evidence). Combination therapy may result in an improvement in QoL (MD –1.49, 95% CI –1.88 to –1.11; low‐certainty evidence). Combination therapy likely results in little to no difference in adverse events (RR 1.26, 95% CI 0.81 to 1.95; moderate‐certainty evidence); based on 115 adverse events per 1000 participants in the anticholinergic alone group, this corresponds to 4 fewer adverse events (95% CI 7 fewer to 13 more) per 1000 participants treated with combination therapy. </p> </section> <section id="CD012336-sec-0007"> <h3 class="title" id="CD012336-sec-0007">Authors' conclusions</h3> <p>Based on the findings of the review, combination therapy with anticholinergics and alpha‐blockers are associated with little or uncertain effects on urologic symptom scores compared to placebo, alpha‐blockers, or anticholinergics monotherapy. However, combination therapy may result in an improvement in quality of life compared to anticholinergics monotherapy, but an uncertain effect compared to placebo, or alpha‐blockers. Combination therapy likely increases adverse events compared to placebo, but not compared to alpha‐blockers or anticholinergics monotherapy. The findings of this review were limited by study limitations, inconsistency, and imprecision. We were unable to conduct any of the predefined subgroup analyses.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012336-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012336-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012336-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012336-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012336-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012336-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012336-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012336-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012336-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012336-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012336-abs-0002" lang="en"> <h3>Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction </h3> <p><b>Review question</b> </p> <p>Is combination therapy with anticholinergics, a type of medicine that can relieve abnormal bladder contraction (where a man cannot control when he urinates), and alpha‐blockers, a type of medicine that can relax the urethral muscle (the tube that carries urine from the bladder out through the penis during urination), effective and safe for managing urination difficulties and urgency related to enlarged prostate? </p> <p><b>Background</b> </p> <p>Urination difficulties and urgency caused by enlarged prostate (a male organ near the bladder and surrounding a part of the urethra) are common in men. Although alpha‐blockers have been used to relieve the urinary symptoms, up to one third of men get no benefit. Combination therapy with alpha‐blockers and anticholinergics provides a treatment option for men with urinary symptoms. </p> <p><b>Study characteristics</b> </p> <p>The search is up‐to‐date to 7 August 2020. We identified 23 studies involving 6285 men. Five studies compared combination therapy with anticholinergics and alpha‐blockers versus placebo (a pill with no therapeutic effects). A total of 22 studies compared combination therapy with anticholinergics and alpha‐blockers versus alpha‐blockers alone. Three studies compared combination therapy with anticholinergics and alpha‐blockers versus anticholinergics alone. The follow‐up period in the studies ranged from 12 weeks to one year. </p> <p><b>Key results</b> </p> <p>Combination therapy versus placebo: combination therapy with anticholinergics and alpha‐blockers was associated with little effect in urinary symptoms and uncertain improvement on quality of life, but combination therapy may increase unwanted side effects. </p> <p>Combination therapy versus alpha‐blockers: combination therapy with anticholinergics and alpha‐blockers may have uncertain effects on improvement of urinary symptoms and quality of life compared to alpha‐blockers alone. Combination therapy may not increase unwanted side effects. </p> <p>Combination therapy compared to anticholinergics: combination therapy with anticholinergics and alpha‐blockers may be associated with uncertain effects on urinary symptoms, but an improvement in quality of life in comparison with anticholinergics alone. Combination therapy may not increase unwanted side effects. </p> <p><b>Quality of the evidence</b> </p> <p>A majority of included studies were not well conducted or reported, which is why we rated down the certainty of evidence (the confidence to state the conclusion is right) to moderate, low or very low. This means that the true effect may be substantially different from what this review found. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012336-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012336-sec-0107"></div> <h3 class="title" id="CD012336-sec-0108">Implications for practice</h3> <section id="CD012336-sec-0108"> <p>Based on the findings of the review, combination therapy with anticholinergics and alpha‐blockers was associated with little or uncertain effects on urologic symptom scores compared to placebo, alpha‐blockers, or anticholinergics monotherapy. However, combination therapy may result in an improvement in quality of life compared to anticholinergics monotherapy, but an uncertain effect compared to placebo, or alpha‐blockers. Combination therapy likely increases adverse events compared to placebo, but not compared to alpha‐blockers or anticholinergics monotherapy. </p> </section> <h3 class="title" id="CD012336-sec-0109">Implications for research</h3> <section id="CD012336-sec-0109"> <p>Given the very low‐ to low‐certainty evidence that characterizes most of the reported analyses, there is need for additional research to explore the effectiveness and safety of combination therapy on lower urinary tract symptoms/benign prostatic obstruction. Future trials should be conducted according to higher methodological standards with regards to allocation concealment and blinding to minimize concerns about selection, performance, and detection bias. Furthermore, trials with long‐term follow‐up are also needed to assess the long‐term efficacy and safety of combination therapy. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012336-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012336-sec-0008"></div> <div class="table" id="CD012336-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Combination therapy versus placebo for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Combination therapy versus placebo for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with lower urinary tract symptoms related to benign prostatic obstruction<br/><b>Setting:</b> multi‐center/outpatients/China, USA, Europe<br/><b>Intervention:</b> combination therapy<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo (short term)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with combination therapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urologic symptom scores</b><br/>assessed with: IPSS<br/>Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/>Follow‐up: range 12–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1792<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of urologic symptom scores ranged from –7.2 to –5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 2.73 lower</b><br/>(5.55 lower to 0.08 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b><br/>assessed with: IPSS‐QoL<br/>Scale from: 0 (delighted) to 6 (terrible)<br/>Follow‐up: range 12–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>991<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of QoL ranged from –1.6 to –0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.97 lower</b><br/>(2.11 lower to 0.16 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1848<br/>(3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.24</b><br/>(1.04 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 more per 1000<br/>(10 more to 119 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>AUR</b><br/>Follow‐up: range 12–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2369<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.94</b><br/>(0.41 to 9.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Surgical intervention</b> – not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AUR:</b> acute urinary retention; <b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: unclear or high risk of bias in one or more domain for selection, attrition, or reporting bias in half or more included studies.<br/><sup>b</sup>Not downgraded for inconsistency despite substantial or considerable heterogeneity: study limitations of <a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a> may cause inconsistency.<br/><sup>c</sup>Downgraded one level for inconsistency: substantial or considerable heterogeneity.<br/><sup>d</sup>Downgraded one level for imprecision: confidence interval crossed assumed threshold of clinically important difference.<br/><sup>e</sup>Downgraded two levels for imprecision: wide confidence interval crossed assumed threshold of clinically important difference and very rare event.<br/><sup>f</sup>No event in control group. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012336-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Combination therapy versus alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Combination therapy versus alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with lower urinary tract symptoms related to benign prostatic obstruction<br/><b>Setting:</b> outpatients/Asia, USA, Europe<br/><b>Intervention:</b> combination therapy<br/><b>Comparison:</b> alpha‐blockers </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with alpha‐blockers (short term)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with combination therapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urologic symptom scores</b><br/>assessed with: IPSS<br/>Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/>Follow‐up: range 12 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3631<br/>(19 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of urologic symptom scores ranged from –11.9 to –2.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 2.04 lower</b><br/>(3.56 lower to 0.52 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b><br/>assessed with: IPSS‐QoL<br/>Scale from: 0 (delighted) to 6 (terrible)<br/>Follow‐up: range 12 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2687<br/>(15 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of QoL ranged from –2.9 to 0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.71 lower</b><br/>(1.03 lower to 0.38 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>Follow‐up: range 12 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3561<br/>(12 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.10</b><br/>(0.90 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 more per 1000<br/>(23 fewer to 78 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>AUR</b><br/>Follow‐up: range 12 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4669<br/>(19 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.03</b><br/>(0.97 to 4.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000<br/>(0 to 12 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Surgical intervention</b><br/>Follow‐up: range 12–26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>454<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>d</sup><sup>,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.72</b><br/>(0.34 to 8.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 more per 1000<br/>(77 fewer to 424 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AUR:</b> acute urinary retention; <b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>QoL:</b> quality of life. <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: unclear or high risk of bias in one or more domain in half or more included studies.<br/><sup>b</sup>Downgraded one level for imprecision: confidence interval crossed assumed threshold of clinically important difference.<br/><sup>c</sup>Downgraded one level for inconsistency: substantial or considerable heterogeneity.<br/><sup>d</sup>Downgraded one level for study limitations: unclear or high risk of selection, performance, detection, reporting bias.<br/><sup>e</sup>Downgraded two levels for imprecision: wide confidence interval crossed assumed threshold of clinically important difference and very rare event.<br/><sup>f</sup>No event in control group. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012336-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Combination therapy versus anticholinergics for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Combination therapy versus anticholinergics for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with lower urinary tract symptoms related to benign prostatic obstruction<br/><b>Setting:</b> multi‐center/outpatients/China, USA, Europe<br/><b>Intervention:</b> combination therapy<br/><b>Comparison:</b> anticholinergics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with anticholinergics (short term)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with combination therapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urologic symptom scores</b><br/>assessed with: IPSS<br/>Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/>Follow‐up: range 12–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>710<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of urologic symptom scores ranged from –6.5 to –5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 3.71 lower</b><br/>(9.41 lower to 1.98 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b><br/>assessed with: IPSS‐QoL<br/>Scale from: 0 (delighted) to 6 (terrible)<br/>Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of QoL was –1.41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.49 lower</b><br/>(1.88 lower to 1.11 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>661<br/>(1 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.26</b><br/>(0.81 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 more per 1000<br/>(29 fewer to 147 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>AUR</b><br/>Follow‐up: range 12–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1178<br/>(3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.55</b><br/>(0.11 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 fewer per 1000<br/>(7 fewer to 13 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Surgical intervention</b> – not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AUR:</b> acute urinary retention; <b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: unclear or high risk of bias in one or more domain for selection, attrition, or reporting bias.<br/><sup>b</sup>Downgraded one level for inconsistency: substantial or considerable heterogeneity.<br/><sup>c</sup>Downgraded one level for imprecision: confidence interval crossed assumed threshold of clinically important difference.<br/><sup>d</sup>Downgraded one level for imprecision: insufficient information size.<br/><sup>e</sup>Wide confidence interval in relative effect, but small risk difference in absolute effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012336-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012336-sec-0009"></div> <section id="CD012336-sec-0010"> <h3 class="title" id="CD012336-sec-0010">Description of the condition</h3> <p>Lower urinary tract symptoms (LUTS) are a complaint in elderly men (<a href="./references#CD012336-bbs2-0087" title="OelkeM , BachmannA , DescazeaudA , EmbertonM , GravasS , MichelMC , et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European Urology2013;64(1):118-40. [PMID: 23541338]">Oelke 2013</a>). Benign prostatic obstruction (BPO) is a main etiology for aging men to experience LUTS and it differs from benign prostatic hyperplasia (BPH) and benign prostatic enlargement (BPE). BPH is a histologic diagnosis characterized by the proliferation of epithelial and stromal cells within the prostate gland (<a href="./references#CD012336-bbs2-0070" title="HansenBJ , FlygerH , BrassoK , SchouJ , NordlingJ , Thorup AndersenJ , et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. British Journal of Urology1995;76(4):451-8. [PMID: 7551880]">Hansen 1995</a>). BPE refers to an increase in volume of the prostate due to BPH. BPO is an obstruction that results from BPE, which can be confirmed by pressure flow studies, or be highly suspected from flow rates and if the gland is enlarged (<a href="./references#CD012336-bbs2-0050" title="AbramsP , ChappleC , KhouryS , RoehrbornC , dela RosetteJ , 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases. Evaluation and treatment of lower urinary tract symptoms in older men. Journal of Urology2013;189(1 Suppl):S93-101. [PMID: 23234640]">Abrams 2013</a>). The prevalence of LUTS/BPH varies in different studies, ranging from 39% to 90% (<a href="./references#CD012336-bbs2-0071" title="HansenBL . Lower urinary tract symptoms (LUTS) and sexual function in both sexes. European Urology2004;46(2):229-34.">Hansen 2004</a>; <a href="./references#CD012336-bbs2-0094" title="SeftelAD , dela RosetteJ , BirtJ , PorterV , ZarotskyV , ViktrupL . Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. International Journal of Clinical Practice2013;67(1):32-45.">Seftel 2013</a>; <a href="./references#CD012336-bbs2-0095" title="SolvangM , ElnegaardS , JarbolDE . Urological symptoms among 23,240 men in the general danish population – concerns about symptoms, their persistence and influence on primary care contacts. Scandinavian Journal of Primary Health Care2018;36(3):227-36.">Solvang 2018</a>), and rises significantly with increased age. It is estimated that 70% of men between 60 and 70 years old and 80% of men over 70 years old are affected by BPH in the USA (<a href="./references#CD012336-bbs2-0100" title="WeiJT , CalhounE , JacobsenSJ . Urologic diseases in America project: benign prostatic hyperplasia. Journal of Urology2005;173(4):1256-61. [PMID: 15758764]">Wei 2005</a>). Based on one prospective, community‐based cohort study, the Rancho Bernardo study, 56% of men younger than 80 years of age, 70% of men 80 to 89 years of age, and 90% of men older than 90 years of age experience LUTS (<a href="./references#CD012336-bbs2-0088" title="ParsonsJK , BergstromJ , SilbersteinJ , Barrett-ConnorE . Prevalence and characteristics of lower urinary tract symptoms in men aged ≥ 80 years. Urology2008;72(2):318-21. [PMID: 18554695]">Parsons 2008</a>). According to the result from one Chinese national cross‐sectional survey, the adjusted odds ratio (OR) for the prevalence of LUTS/BPH is 1.50 (95% confidence intervals (CI) 1.20 to 1.87) in men aged 60 to 69 years and 2.09 (95% CI 1.58 to 2.78) in men aged more than 70 years compared to men aged less than 60 years (<a href="./references#CD012336-bbs2-0107" title="ZhangW , ZhangX , LiH , WuF , WangH , ZhaoM , et al. Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in China: results from the China Health and Retirement Longitudinal Study. BMJ Open2019;9(6):e022792. [PMID: 31221864]">Zhang 2019</a>). In general, LUTS are divided into storage LUTS (increased daytime frequency, nocturia, urgency, and incontinence), voiding LUTS (slow stream, splitting or spraying, intermittent stream, hesitancy, straining, and terminal dribble), and postmicturition LUTS (feeling of incomplete emptying and postmicturition dribble) (<a href="./references#CD012336-bbs2-0049" title="AbramsP , CardozoL , FallM , GriffithsD , RosierP , UlmstenU , et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourology and Urodynamics2002;21(2):167-78. [PMID: 11857671]">Abrams 2002</a>). All the symptoms significantly reduce men's quality of life (QoL) and storage LUTS is more bothersome compared to voiding LUTS (<a href="./references#CD012336-bbs2-0085" title="National Institute for Health and Care Excellence. Lower urinary tract symptoms in men: management (Clinical Guideline 97). www.nice.org.uk/guidance/CG97 (accessed prior to 10 November 2020).">NICE 2015</a>). Besides the negative impact on public health, the cost related to LUTS has been a social and economic burden. During 2000, the direct treatment expenditure for LUTS related to BPO was USD 1.1 billion in the USA (<a href="./references#CD012336-bbs2-0101" title="WeiJT , CalhounE , JacobsenSJ . Urologic diseases in America project: benign prostatic hyperplasia. Journal of Urology2008;179(5 Suppl):S75-80. [PMID: 18405761]">Wei 2008</a>). Based on Hospital Episode Statistics data (2007 to 2008), LUTS secondary to BPO have been the fifth most expensive disease to the UK National Health Service (NHS) and account for a cost of GBP 1.16 billion each year (<a href="./references#CD012336-bbs2-0077" title="KirbyRS , KirbyM , FitzpatrickJM . Benign prostatic hyperplasia: counting the cost of its management. BJU International2010;105(7):901-2. [PMID: 20356323]">Kirby 2010</a>). The TRIUMPH study found the annual cost for LUTS suggestive of BPH ranged from EUR 292 to EUR 1337 per patient in six European countries (<a href="./references#CD012336-bbs2-0097" title="Van ExelNJ , KoopmanschapMA , McDonnellJ , ChappleCR , BergesR , RuttenFF , et al. Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. European Urology2006;49(1):92-102.">Van Exel 2006</a>). </p> </section> <section id="CD012336-sec-0011"> <h3 class="title" id="CD012336-sec-0011">Description of the intervention</h3> <p>Alpha‐adrenergic antagonists (alpha‐blockers) have been considered as the first‐line pharmacotherapy for men with LUTS related to BPO due to their well‐documented efficacy (<a href="./references#CD012336-bbs2-0066" title="GravasS , BachT , BachmannA , DrakeM , GacciM , GratzkeC , et al. Treatment of non-neurogenic male LUTS. uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/ (accessed 22 August 2016).">Gravas 2015</a>). It is confirmed that alpha‐blockers can relieve BPO by decreasing smooth muscle tone in the prostate and bladder neck (<a href="./references#CD012336-bbs2-0055" title="ChappleCR . Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU International2004;94(5):738-44. [PMID: 15329091]">Chapple 2004</a>). The American Urological Association (AUA) has determined that the alpha‐blockers alfuzosin, doxazosin, tamsulosin, and terazosin are appropriate and effective treatments for men with LUTS secondary to BPO (<a href="./references#CD012336-bbs2-0084" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793-803. [PMID: 21420124]">McVary 2011</a>). Clinical studies have shown that these alpha‐blockers can typically reduce the International Prostate Symptom Score (IPSS) by approximately 20% to 50% and increase the maximum urine flow (Qmax) by approximately 15% to 45% (<a href="./references#CD012336-bbs2-0082" title="MacDonaldR , WiltTJ . Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology2005;66(4):780-8. [PMID: 16230138]">MacDonald 2005</a>; <a href="./references#CD012336-bbs2-0102" title="WiltTJ , MacDonaldR . Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clinical Interventions in Aging2006;1(4):389-401. [PMID: 18046916]">Wilt 2006</a>). One study further showed that alpha‐blockers could improve Qmax more effectively in younger men (less than 65 years old) as compared to older men (65 years and older) (<a href="./references#CD012336-bbs2-0086" title="NovaraG , ChappleCR , MontorsiF . Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data. BJU International2015;115(5):802-14. [PMID: 25130493]">Novara 2015</a>). Furthermore, one systematic review and meta‐analysis suggests that evaluation using Qmax may underestimate a real effect of alpha‐blockers on BPO, since urodynamic study confirms that small improvements in Qmax correspond to relevant improvements in BPO (<a href="./references#CD012336-bbs2-0063" title="FuscoF , PalmieriA , FicarraV , GiannariniG , NovaraG , LongoN , et al. Alpha1-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. European Urology2016;69(6):1091-101. [PMID: 26831507]">Fusco 2016</a>). Adverse effects of alpha‐blockers include postural hypotension, dizziness, headache, asthenia, syncope, peripheral edema, retrograde ejaculation and intraoperative floppy iris syndrome, which cause approximately 4% to 10% of men to withdraw from alpha‐blocker treatment (<a href="./references#CD012336-bbs2-0059" title="DjavanB , MarbergerM . A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. European Urology1999;36(1):1-13. [PMID: 10364649]">Djavan 1999</a>; <a href="./references#CD012336-bbs2-0106" title="YuZJ , YanHL , XuFH , ChaoHC , DengLH , XuXD , et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Frontiers in Pharmacology2020;11:658.">Yu 2020</a>). </p> <p>Anticholinergics are considered as one of the standard pharmacotherapies for people with overactive bladder (<a href="./references#CD012336-bbs2-0064" title="GormleyEA , LightnerDJ , FaradayM , VasavadaSP , American Urological Association, Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. Journal of Urology2015;193(5):1572-80. [PMID: 25623739]">Gormley 2015</a>). These agents can block the combination of acetylcholine and muscarinic receptors on detrusor smooth muscle, which can improve storage LUTS by relieving the detrusor overactivity (<a href="./references#CD012336-bbs2-0051" title="AnderssonKE . Antimuscarinics for treatment of overactive bladder. Lancet Neurology2004;3(1):46-53. [PMID: 14693111]">Andersson 2004</a>; <a href="./references#CD012336-bbs2-0091" title="ReynardJM . Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents?Current Opinion in Urology2004;14(1):13-6. [PMID: 15091043]">Reynard 2004</a>). The licensed agents for treating storage LUTS include darifenacin, fesoterodine, imidafenacin, oxybutynin, propiverine, solifenacin, tolterodine, and trospium chloride (<a href="./references#CD012336-bbs2-0066" title="GravasS , BachT , BachmannA , DrakeM , GacciM , GratzkeC , et al. Treatment of non-neurogenic male LUTS. uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/ (accessed 22 August 2016).">Gravas 2015</a>; <a href="./references#CD012336-bbs2-0104" title="YamadaS , ItoY , NishijimaS , KadekawaK , SugayaK . Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacology &amp; Therapeutics2018;189:130-48.">Yamada 2018</a>). Adverse effects of anticholinergics mainly include dry mouth, pruritus, constipation, micturition difficulties, nasopharyngitis, and dizziness (<a href="./references#CD012336-bbs2-0106" title="YuZJ , YanHL , XuFH , ChaoHC , DengLH , XuXD , et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Frontiers in Pharmacology2020;11:658.">Yu 2020</a>). Moreover, as the most serious adverse effect, anticholinergics may lead to acute urinary retention (AUR) due to their inhibitory action on detrusor contraction (<a href="./references#CD012336-bbs2-0106" title="YuZJ , YanHL , XuFH , ChaoHC , DengLH , XuXD , et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Frontiers in Pharmacology2020;11:658.">Yu 2020</a>). One retrospective cohort study revealed that the short term (30 days or fewer) and long term (more than 30 days) use of anticholinergics were associated with a relative risk of AUR of 8.3 (short term) and 2.0 (long term) (<a href="./references#CD012336-bbs2-0083" title="Martin-MerinoE , Garcia-RodriguezLA , Masso-GonzalezEL , RoehrbornCG . Do oral antimuscarinic drugs carry an increased risk of acute urinary retention?Journal of Urology2009;182(4):1442-8.">Martin‐Merino 2009</a>). Additionally, it has been shown that cumulative anticholinergic exposure is associated with an increased risk of dementia (<a href="./references#CD012336-bbs2-0058" title="CouplandCA , HillT , DeningT , MorrissR , MooreM , Hippisley-CoxJ . Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Internal Medicine2019;179(8):1084-93. [PMID: 31233095]">Coupland 2019</a>; <a href="./references#CD012336-bbs2-0099" title="WangYC , ChenYL , HuangCC , HoCH , HuangYT , WuMP , et al. Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study. BMC Geriatrics2019;18:380. [PMID: 31888519]">Wang 2019</a>). </p> <p>Combination therapy with an alpha‐blocker and an anticholinergic can achieve synergistic effect of these two classes of drugs by blocking both alpha‐adrenergic receptors and muscarinic cholinergic receptors in the lower urinary tract. Randomized controlled trials (RCTs) (<a href="./references#CD012336-bbs2-0056" title="ChappleC , HerschornS , AbramsP , SunF , BrodskyM , GuanZ . Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. European Urology2009;56(3):534-41. [PMID: 19070418]">Chapple 2009</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0098" title="Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [PMID: 23932438]">Van Kerrebroeck 2013a</a>; <a href="./references#CD012336-bbs2-0105" title="YamaguchiO , KakizakiH , HommaY , TakedaM , NishizawaO , GotohM , et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms – ASSIST, randomized controlled study. Urology2011;78(1):126-33. [PMID: 21601248]">Yamaguchi 2011</a>), and RCT‐based meta‐analyses (<a href="./references#CD012336-bbs2-0061" title="FilsonCP , HollingsworthJM , ClemensJQ , WeiJT . The efficacy and safety of combined therapy with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. Journal of Urology2013;190(6):2153-60. [PMID: 23727412]">Filson 2013</a>; <a href="./references#CD012336-bbs2-0103" title="XinZ , HuangY , LuJ , ZhangQ , ChenC . Addition of antimuscarinics to alpha-blockers for treatment of lower urinary tract symptoms in men: a meta-analysis. Urology2013;82(2):270-7. [PMID: 23896090]">Xin 2013</a>), have provided evidence for the advantage of combination therapy in management of male storage LUTS. </p> </section> <section id="CD012336-sec-0012"> <h3 class="title" id="CD012336-sec-0012">How the intervention might work</h3> <p>There are two types of alpha‐adrenergic receptors, alpha‐1 receptor and alpha‐2 receptor, in human central and peripheral nervous systems. Of those, alpha‐1 receptors are mainly located on the urinary bladder base and prostatic urethra (<a href="./references#CD012336-bbs2-0080" title="KunisawaY , KawabeK , NiijimaT , HondaK , TakenakaT . A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra. Journal of Urology1985;134(2):396-8. [PMID: 2991614]">Kunisawa 1985</a>). There are three different alpha‐1 receptor subtypes: alpha‐1A, alpha‐1B, and alpha‐1D (<a href="./references#CD012336-bbs2-0087" title="OelkeM , BachmannA , DescazeaudA , EmbertonM , GravasS , MichelMC , et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European Urology2013;64(1):118-40. [PMID: 23541338]">Oelke 2013</a>). Alpha‐1A subtype primarily mediates smooth muscle tone in the prostate and bladder neck, while alpha‐1B subtype generally mediates vascular smooth muscle contraction (<a href="./references#CD012336-bbs2-0062" title="FineSR , GinsbergP . Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications. Journal of the American Osteopathic Association2008;108(7):333-7. [PMID: 18648026]">Fine 2008</a>). The alpha‐1D subtype is believed to function as a mediator for lower urinary tract function through regulation of bladder muscle contraction and sacral spinal cord innervation (<a href="./references#CD012336-bbs2-0062" title="FineSR , GinsbergP . Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications. Journal of the American Osteopathic Association2008;108(7):333-7. [PMID: 18648026]">Fine 2008</a>). alpha‐blockers can inhibit the activation of these alpha‐1 receptors, which results in decreased intracellular Ca<sup>2+</sup> and subsequently causes smooth muscle relaxation. Consequently, the prostatic urethral opening secondary to smooth muscle relaxation can help men to relieve their voiding LUTS. </p> <p>Acetylcholine is the predominant neurotransmitter in the lower urinary tract that can combine with muscarinic receptors on the surface of various cells, such as smooth muscle cells, urothelial cells, nerve cells, or epithelial cells. Five different muscarinic receptor subtypes have been identified in humans: M<sub>1</sub>, M<sub>2</sub>, M<sub>3</sub>, M<sub>4</sub>, and M<sub>5</sub> receptors. Of these, M<sub>2</sub> and M<sub>3</sub> subtypes primarily express on the surface of the detrusor muscle, which is involved in bladder contractions (<a href="./references#CD012336-bbs2-0054" title="BravermanAS , DoumanianLR , Ruggieri MR Sr. M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder. Journal of Pharmacology and Experimental Therapeutics2006;316(2):875-80. [PMID: 16243962]">Braverman 2006</a>; <a href="./references#CD012336-bbs2-0057" title="Chess-WilliamsR , ChappleCR , YamanishiT , YasudaK , SellersDJ . The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. Journal of Autonomic Pharmacology2001;21(5-6):243-8. [PMID: 12123469]">Chess‐Williams 2001</a>). Anticholinergics can inhibit the activation of these two subtypes of muscarinic receptors, which suppresses the release of Ca<sup>2+</sup> mediated by G‐protein and the opening of calcium channels in cell membranes, and, consequently, results in the relaxation of the detrusor muscle. The detrusor relaxation allows the bladder to store more urine, which can help men to relieve their storage LUTS. </p> <p>Combination therapy with alpha‐blockers and anticholinergics can inhibit alpha‐adrenergic and muscarinic receptors simultaneously, which may improve LUTS related to BPO. </p> </section> <section id="CD012336-sec-0013"> <h3 class="title" id="CD012336-sec-0013">Why it is important to do this review</h3> <p>Although voiding and postmicturition LUTS are typically related to BPO (<a href="./references#CD012336-bbs2-0049" title="AbramsP , CardozoL , FallM , GriffithsD , RosierP , UlmstenU , et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourology and Urodynamics2002;21(2):167-78. [PMID: 11857671]">Abrams 2002</a>), as many as 50% of men with BPO experience storage LUTS (<a href="./references#CD012336-bbs2-0091" title="ReynardJM . Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents?Current Opinion in Urology2004;14(1):13-6. [PMID: 15091043]">Reynard 2004</a>). Alpha‐blockers are considered the first‐line drug for men with LUTS secondary to BPO (<a href="./references#CD012336-bbs2-0066" title="GravasS , BachT , BachmannA , DrakeM , GacciM , GratzkeC , et al. Treatment of non-neurogenic male LUTS. uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/ (accessed 22 August 2016).">Gravas 2015</a>; <a href="./references#CD012336-bbs2-0106" title="YuZJ , YanHL , XuFH , ChaoHC , DengLH , XuXD , et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Frontiers in Pharmacology2020;11:658.">Yu 2020</a>), but up to one third of men report no improvement in their LUTS (<a href="./references#CD012336-bbs2-0059" title="DjavanB , MarbergerM . A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. European Urology1999;36(1):1-13. [PMID: 10364649]">Djavan 1999</a>), especially storage LUTS, after taking this drug. To relieve storage LUTS more effectively, combination therapy with alpha‐blockers and anticholinergics has been tried in some clinical trials. However, the results are inconsistent due to different study designs, which causes the effect of combination therapy with alpha‐blockers and anticholinergics on LUTS to be controversial. Moreover, it is reported that anticholinergics may result in urinary retention in men with BPO (<a href="./references#CD012336-bbs2-0096" title="Vande GriendJP , LinneburSA . Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia. Annals of Pharmacotherapy2012;46(9):1245-9. [PMID: 22851743]">Vande Griend 2012</a>; <a href="./references#CD012336-bbs2-0108" title="ZhouX , YanHL , CuiYS , ZongHT , ZhangY . Efficacy and safety of onabotulinumtoxin A in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chinese Medical Journal2015;128(7):963-8. [PMID: 25836619]">Zhou 2015</a>). Additionally, the long‐term effects of combination therapy with alpha‐blockers and anticholinergics for LUTS related to BPO are unclear. Therefore, it is desirable to conduct a systematic review. Although two systematic reviews and meta‐analyses have shown that combination therapy is associated with greater benefit than alpha‐blockers monotherapy (<a href="./references#CD012336-bbs2-0061" title="FilsonCP , HollingsworthJM , ClemensJQ , WeiJT . The efficacy and safety of combined therapy with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. Journal of Urology2013;190(6):2153-60. [PMID: 23727412]">Filson 2013</a>; <a href="./references#CD012336-bbs2-0103" title="XinZ , HuangY , LuJ , ZhangQ , ChenC . Addition of antimuscarinics to alpha-blockers for treatment of lower urinary tract symptoms in men: a meta-analysis. Urology2013;82(2):270-7. [PMID: 23896090]">Xin 2013</a>), some later trials revealed that the addition of anticholinergics cannot further improve LUTS secondary to BPO (<a href="./references#CD012336-bbs2-0078" title="KoK , YangDY , LeeWK , KimSW , Moon duG , MoonKH , et al. Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin. Korean Journal of Urology2014;55(9):608-14. [PMID: 25237463]">Ko 2014</a>; <a href="./references#CD012336-bbs2-0035" title="LeeSH , ByunSS , LeeSJ , KimKH , LeeJY . Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study. International Urology and Nephrology2014;46(3):523-9. [DOI: 10.1007/s11255-013-0551-7]">Lee 2014</a>). There have been no recent systematic reviews to further analyze the efficacy of combination therapy. In addition, unlike the published meta‐analyses, this systematic review will use the GRADE approach to rate the certainty of the evidence. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012336-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012336-sec-0014"></div> <p>To assess the effects of combination therapy with anticholinergics and alpha‐blockers in men with LUTS related to BPO. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012336-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012336-sec-0015"></div> <section id="CD012336-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012336-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included parallel‐group RCTs. We excluded quasi‐randomized studies, cross‐over studies, cluster‐randomized studies, and observational studies (cohort, case‐control, and cross‐sectional). We included studies regardless of their publication status or language of publication. </p> </section> <section id="CD012336-sec-0018"> <h4 class="title">Types of participants</h4> <p>Men with LUTS secondary to BPO that was confirmed by pressure flow studies, or highly suspected from flow rates when an enlarged prostate volume was detected (<a href="./references#CD012336-bbs2-0050" title="AbramsP , ChappleC , KhouryS , RoehrbornC , dela RosetteJ , 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases. Evaluation and treatment of lower urinary tract symptoms in older men. Journal of Urology2013;189(1 Suppl):S93-101. [PMID: 23234640]">Abrams 2013</a>), ages 40 years or older (since hyperplasia of the prostate gland starts at approximately 40 years of age; <a href="./references#CD012336-bbs2-0053" title="BerrySJ , CoffeyDS , WalshPC , EwingLL . The development of human benign prostatic hyperplasia with age. Journal of Urology1984;132(3):474-9. [DOI: 10.1016/s0022-5347(17)49698-4]">Berry 1984</a>; <a href="./references#CD012336-bbs2-0089" title="RamsamyK , SubramaniyanR , PatraAK . An observational study of the association between androgenetic alopecia and size of the prostate. International Journal of Trichology2016;8(2):62-6. [DOI: 10.4103/0974-7753.188034]">Ramsamy 2016</a>), and a total IPSS of 8 or greater. </p> <p>We excluded trials of men with a known neurogenic bladder due to spinal cord injury, multiple sclerosis, or central nervous system disease. We also excluded studies that examined medical therapy for men treated with surgery for BPO. </p> <p>We included studies in which only a subset of participants was relevant to this review, if data were available separately for the relevant subset. </p> </section> <section id="CD012336-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We performed the following comparisons.</p> <p> <ul id="CD012336-list-0001"> <li> <p>Combination therapy with anticholinergics (e.g. darifenacin, fesoterodine, imidafenacin, oxybutynin, propiverine, solifenacin, tolterodine, and trospium chloride) and alpha‐blockers (e.g. alfuzosin, doxazosin, naftopidil, silodosin, tamsulosin, and terazosin) versus placebo. </p> </li> <li> <p>Combination therapy with anticholinergics and alpha‐blockers versus other medical treatments for LUTS related to BPO, including alpha‐blockers monotherapy and anticholinergics monotherapy. </p> </li> </ul> </p> </section> <section id="CD012336-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We did not use the measurement of the outcomes assessed in this review as an eligibility criterion. We calculated the minimal clinically important difference (MCID) for each outcome to aid our interpretation of the results. We considered outcomes measured up to and including 12 months after randomization as short term, and beyond 12 months as long term. </p> <section id="CD012336-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012336-list-0002"> <li> <p>Urologic symptom scores: change from baseline assessed with a validated scale (such as the IPSS; an MCID of 3 points in the IPSS was used to assess the clinically meaningful improvement, as defined by the AUA (<a href="./references#CD012336-bbs2-0052" title="American Urological Association. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (2018). www.auanet.org/guidelines/benign-prostatic-hyperplasia/lower-urinary-tract-symptoms-(2018) (accessed 3 October 2018).">AUA 2018</a>)). For studies that only reported final values, we combined these final values with changes from baseline for meta‐analysis. </p> </li> <li> <p>QoL: change from baseline assessed with IPSS bother score (we used an MCID of 1 point for IPSS‐QoL (<a href="./references#CD012336-bbs2-0052" title="American Urological Association. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (2018). www.auanet.org/guidelines/benign-prostatic-hyperplasia/lower-urinary-tract-symptoms-(2018) (accessed 3 October 2018).">AUA 2018</a>)). For studies that only reported final values, we combined these final values with changes from baseline for meta‐analysis. </p> </li> <li> <p>Adverse events: adverse events graded as the Common Terminology Criteria for Adverse Events (CTCAE): Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life‐threatening or disabling; Grade 5 = death‐related; we considered the definition the trial authors used in each clinical trial). We considered the MCID for adverse events as a relative risk reduction of at least 25% (<a href="./references#CD012336-bbs2-0068" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [PMID: 21839614]">Guyatt 2011a</a>). </p> </li> </ul> </p> </section> <section id="CD012336-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012336-list-0003"> <li> <p>AUR: events requiring catheterization after intervention with an MCID defined as relative risk reduction of at least 25% (<a href="./references#CD012336-bbs2-0068" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [PMID: 21839614]">Guyatt 2011a</a>). </p> </li> <li> <p>Surgical intervention: events requiring other surgical treatment modalities (e.g. transurethral resection of the prostate (TURP)) after intervention with an MCID defined as relative risk reduction of at least 25% (<a href="./references#CD012336-bbs2-0068" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [PMID: 21839614]">Guyatt 2011a</a>). </p> </li> </ul> </p> <section id="CD012336-sec-0023"> <h6 class="title">Main outcomes for 'Summary of findings' table</h6> <p>We presented a 'Summary of findings' table and reported the following outcomes, which we have listed according to priority. </p> <p> <ul id="CD012336-list-0004"> <li> <p>Urologic symptom scores.</p> </li> <li> <p>QoL.</p> </li> <li> <p>Adverse effects.</p> </li> <li> <p>AUR.</p> </li> <li> <p>Surgical intervention.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012336-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <p>We performed a comprehensive search with no restrictions on the language of publication or publication status. We plan to rerun searches within three months prior to anticipated publication of the review. </p> <section id="CD012336-sec-0025"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic sources on 7 August 2020.</p> <p> <ul id="CD012336-list-0005"> <li> <p>The Cochrane Library via Wiley (from 1990 to present) (<a href="./appendices#CD012336-sec-0113">Appendix 1</a>): </p> <ul id="CD012336-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>Health Technology Assessment Database (HTA).</p> </li> </ul> </li> <li> <p>MEDLINE via PubMed (1953 to present) (<a href="./appendices#CD012336-sec-0114">Appendix 2</a>). </p> </li> <li> <p>Embase via Elsevier (1947 to present) (<a href="./appendices#CD012336-sec-0115">Appendix 3</a>). </p> </li> <li> <p>Web of Science, Core Collection (1975 to present) (<a href="./appendices#CD012336-sec-0116">Appendix 4</a>): </p> <ul id="CD012336-list-0007"> <li> <p>Science Citation Index;</p> </li> <li> <p>Conference Proceedings Citation Index.</p> </li> </ul> </li> <li> <p>Chinese Biomedical Literature Database via SinoMed (1978 to present) (search in Chinese) (<a href="./appendices#CD012336-sec-0117">Appendix 5</a>). </p> </li> <li> <p>Latin American and Caribbean Health Sciences Literature (1982 to present) (<a href="./appendices#CD012336-sec-0118">Appendix 6</a>). </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>) (<a href="./appendices#CD012336-sec-0119">Appendix 7</a>). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (<a href="./appendices#CD012336-sec-0120">Appendix 8</a>). </p> </li> <li> <p>OpenGrey (<a href="http://www.opengrey.eu/" target="_blank">opengrey.eu/</a>) (<a href="./appendices#CD012336-sec-0121">Appendix 9</a>). </p> </li> </ul> </p> <p>We presented the search strategy for each electronic sources in the appendices of the review. </p> </section> <section id="CD012336-sec-0026"> <h4 class="title">Searching other resources</h4> <p>We identified other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, reviews, meta‐analyses, and health technology assessment reports. We contacted producers/manufacturers of currently available anticholinergics and alpha‐blockers to identify ongoing or unpublished trials. We searched the abstracts of relevant meetings of the AUA (<a href="http://auanet.org/" target="_blank">auanet.org/</a>) and the International Continence Society (<a href="http://ics.org" target="_blank">ics.org</a>) from 2015 to 2018. </p> </section> </section> <section id="CD012336-sec-0027"> <h3 class="title" id="CD012336-sec-0027">Data collection and analysis</h3> <section id="CD012336-sec-0028"> <h4 class="title">Selection of studies</h4> <p>We used reference management software to identify and remove potential duplicate records (<a href="./references#CD012336-bbs2-0060" title="EndNote. Version X7. Philadelphia: Clarivate Analytics, 2016.">EndNote 2016</a>). Two review authors (RP, XYZ) independently assessed the titles, abstract, or both, of records we identified from the literature searches against the predefined inclusion criteria to determine which studies to assess further. Two review authors (RP, XYZ) investigated all potentially relevant records as full‐text articles, mapped records to studies, and classified studies as included studies, excluded studies, studies awaiting classification, or ongoing studies in accordance with the criteria for each provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012336-bbs2-0073" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>). We resolved any discrepancies through discussion or arbitration by a third review author (XLW). If resolution of a disagreement was not possible, we designated the study as 'awaiting classification' and contacted the study authors for clarification. We documented the reasons for exclusion of studies that may have reasonably been expected to be included in the review in the <a href="./references#CD012336-sec-0134" title="">Characteristics of excluded studies</a> table. We presented an adapted PRISMA flow diagram to show the process of study selection (<a href="./references#CD012336-bbs2-0081" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100]">Liberati 2009</a>). </p> <p>If any records identified in the search were reported in languages other than English or Chinese, we obtained translation assistance (from Prof Chunlan Jin, from the Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences) to English or Chinese to enable assessment. </p> </section> <section id="CD012336-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>We developed a dedicated data abstraction form that we tested for usability.</p> <p>For studies that fulfilled inclusion criteria, two review authors (RP, XYZ) independently abstracted the following information, which we provided in the <a href="./references#CD012336-sec-0133" title="">Characteristics of included studies</a> table. </p> <p> <ul id="CD012336-list-0008"> <li> <p>Study design.</p> </li> <li> <p>Study dates.</p> </li> <li> <p>Study settings and country.</p> </li> <li> <p>Participant inclusion and exclusion criteria.</p> </li> <li> <p>Participant details, baseline demographics.</p> </li> <li> <p>Number of participants by study and by study arm.</p> </li> <li> <p>Details of relevant experimental and comparator interventions such as dose, route, frequency, and duration. </p> </li> <li> <p>Definitions of relevant outcomes, and method and timing of outcome measurement as well as any relevant subgroups. </p> </li> <li> <p>Study funding sources.</p> </li> <li> <p>Declarations of interest by primary investigators.</p> </li> </ul> </p> <p>We extracted outcomes data relevant to this Cochrane Review as needed for calculation of summary statistics and measures of variance. For dichotomous outcomes, we attempted to obtain numbers of events and totals for population of a 2 × 2 table, as well as summary statistics with corresponding measures of variance. For continuous outcomes, we attempted to obtain means and standard deviations (SDs) or data necessary to calculate this information. </p> <p>We resolved any disagreements by discussion, or, if required, we consulted a third review author (XLW). </p> <p>We attempted to contact authors of included studies to obtain key missing data as needed. </p> <section id="CD012336-sec-0030"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents, or multiple reports of a primary study, we maximized the yield of information by mapping all publications to unique studies and collating all available data. We used the most complete data set aggregated across all known publications. In case of doubt, we gave priority to the publication that reported the longest follow‐up associated with our primary or secondary outcomes. </p> </section> </section> <section id="CD012336-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (XLW, BW) independently assessed the risk of bias of each included study. We resolved disagreements by consensus, or we consulted a third review author (RP, JHJ). </p> <p>We assessed the risk of bias of each included study using Cochrane's 'Risk of bias' assessment tool (<a href="./references#CD012336-bbs2-0074" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011b</a>). We assessed the following domains. </p> <p> <ul id="CD012336-list-0009"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Other sources of bias.</p> </li> </ul> </p> <p>We judged 'Risk of bias' domains as 'low risk', 'high risk,' or 'unclear risk' and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012336-bbs2-0074" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011b</a>). We presented a 'Risk of bias' summary figure to illustrate these findings. </p> <p>For selection bias (random sequence generation and allocation concealment), we evaluated risk of bias at a trial level. </p> <p>For performance bias (blinding of participants and personnel), we considered that all outcomes were susceptible to performance bias and assessed in one group. </p> <p>For detection bias (blinding of outcome assessment), we grouped outcomes as susceptible to detection bias (subjective outcomes) or not susceptible to detection bias (objective outcomes). </p> <p>We defined the following endpoints as subjective outcomes:</p> <p> <ul id="CD012336-list-0010"> <li> <p>urologic symptom scores;</p> </li> <li> <p>QoL.</p> </li> </ul> </p> <p>We defined the following endpoints as objective outcomes:</p> <p> <ul id="CD012336-list-0011"> <li> <p>adverse events;</p> </li> <li> <p>AUR;</p> </li> <li> <p>surgical intervention.</p> </li> </ul> </p> <p>We initially assessed attrition bias (incomplete outcome data) on a per‐outcome basis but created groups of outcomes based on similar reporting characteristics. </p> <p>For reporting bias (selective reporting), we evaluated risk of bias on a trial level.</p> </section> <section id="CD012336-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We analyzed the data using Review Manager 5 (<a href="./references#CD012336-bbs2-0090" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). We expressed dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs). We expressed continuous data as mean differences (MDs) with 95% CIs unless different studies use different measures to assess the same outcome, in which case we expressed data as standardized mean differences (SMDs) with 95% CIs. </p> </section> <section id="CD012336-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. When we identified trials with more than two intervention groups for inclusion in the review, we handled these in accordance with guidance provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012336-bbs2-0075" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011c</a>). </p> </section> <section id="CD012336-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We obtained missing data from study authors, if feasible, and performed intention‐to‐treat (ITT) analyses if data were available; we otherwise performed available‐case analyses. We investigated attrition rates (e.g. dropouts, losses to follow‐up, and withdrawals), and critically appraised issues of missing data. We did not impute missing data. </p> </section> <section id="CD012336-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of excessive heterogeneity that was unexplained by subgroup analyses, we did not report outcome results as the pooled effect estimate in a meta‐analysis but provided a narrative description of the results of each study. </p> <p>We assessed the heterogeneity (inconsistency) of included studies using the Chi² test, and we considered a P value less than 0.10 as statistically significant heterogeneity. Furthermore, we measured the quantity of inconsistency using the I² statistic (<a href="./references#CD012336-bbs2-0072" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [PMID: 12958120]">Higgins 2003</a>). We interpret the I² statistic as follows: </p> <p> <ul id="CD012336-list-0012"> <li> <p>0% to 40%, may not be important;</p> </li> <li> <p>30% to 60%, represents moderate heterogeneity;</p> </li> <li> <p>50% to 90%, represents substantial heterogeneity;</p> </li> <li> <p>75% to 100%, represents considerable heterogeneity.</p> </li> </ul> </p> <p>When we found heterogeneity, we attempted to determine the possible reasons for it by examining individual study and subgroup characteristics. </p> </section> <section id="CD012336-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to obtain study protocols to assess for selective outcome reporting.</p> <p>If we included 10 studies or more that investigated a particular outcome, we used funnel plots to assess small‐study effects. Several explanations could be offered for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials), and publication bias. Therefore, we interpreted results carefully. </p> </section> <section id="CD012336-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We summarized the data using a random‐effects model. We interpreted random‐effects meta‐analyses with due consideration of the whole distribution of effects. In addition, we performed statistical analyses according to the statistical guidelines contained in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012336-bbs2-0073" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>). For dichotomous outcomes, we used the Mantel‐Haenszel method; for continuous outcomes, we used the inverse variance method. We used Review Manager 5 to perform analyses (<a href="./references#CD012336-bbs2-0090" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD012336-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity, and planned to perform subgroup analyses limited to primary outcomes and investigate interactions. </p> <p> <ul id="CD012336-list-0013"> <li> <p>Age (less than 65 years versus 65 years or older).</p> </li> <li> <p>Serum prostate‐specific antigen (PSA) level (less than 1.3 ng/mL versus 1.3 ng/mL or greater). </p> </li> <li> <p>IPSS (moderate (8 to 19) versus severe (20 to 35)).</p> </li> </ul> </p> <p>Based on literature in this field (<a href="./references#CD012336-bbs2-0079" title="KozminskiMA , WeiJT , NelsonJ , KentDM . Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH). BJU International2015;115(2):308-16. [PMID: 24825577]">Kozminski 2015</a>), the important characteristics to analyze in LUTS secondary to BPO included age, PSA level, and the IPSS. </p> <p>The results from a secondary analysis of Medical Therapy of Prostatic Symptoms (MTOPS) data showed that age, PSA level, and the IPSS significantly correlate with the progression of LUTS secondary to BPO (<a href="./references#CD012336-bbs2-0079" title="KozminskiMA , WeiJT , NelsonJ , KentDM . Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH). BJU International2015;115(2):308-16. [PMID: 24825577]">Kozminski 2015</a>). Additionally, <a href="./references#CD012336-bbs2-0092" title="RoehrbornCG , KaplanSA , KrausSR , WangJT , BavendamT , GuanZ . Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology2008;72(5):1061-7; discussion 1067. [PMID: 18817961]">Roehrborn 2008</a> suggested that men with PSA levels less than 1.3 ng/mL (smaller prostates) might profit more from anticholinergenic drugs. </p> <p>We used the test for subgroup differences in Review Manager 5 to compare subgroup analyses if there were a sufficient number of included studies (<a href="./references#CD012336-bbs2-0090" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD012336-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses limited to primary outcomes to explore the influence of the following factors (when applicable) on effect sizes: </p> <p> <ul id="CD012336-list-0014"> <li> <p>restricting the analysis by taking into account risk of bias, by exclusion of the studies with non‐blinded design. </p> </li> </ul> </p> </section> <section id="CD012336-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the overall certainty of the evidence for each outcome according to the GRADE approach, which takes into account five criteria related to internal validity (risk of bias, inconsistency, imprecision, publication bias) and also to external validity, such as directness of results (<a href="./references#CD012336-bbs2-0067" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.)2008;336(7650):924-6. [PMID: 18436948]">Guyatt 2008</a>)<i>.</i> For each comparison, two review authors (XLW, BW) independently assessed the certainty of the evidence for each outcome as 'high,' 'moderate,' 'low,' or 'very low' using the GRADEpro Guideline Development Tool (GDT) (<a href="./references#CD012336-bbs2-0065" title="GRADEpro GDT. Version accessed October 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). We resolved any discrepancies by consensus, or, if needed, by arbitration by a third review author (RP, JHJ). For each comparison, we presented a summary of the evidence for the main outcomes in a 'Summary of findings' table, which provides key information about the best estimate of the magnitude of the effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence in effect estimates for each outcome (<a href="./references#CD012336-bbs2-0069" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [DOI: 10.1016/j.jclinepi.2010.04.026]">Guyatt 2011b</a>; <a href="./references#CD012336-bbs2-0093" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012336-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012336-sec-0041"></div> <section id="CD012336-sec-0042"> <h3 class="title">Description of studies</h3> <p>Through database searching, we identified 1656 records (see <a href="#CD012336-fig-0001">Figure 1</a>). We found no additional record through other sources. </p> <div class="figure" id="CD012336-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012336-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <section id="CD012336-sec-0043"> <h4 class="title">Results of the search</h4> <p>After removal of duplicates, we screened the titles and abstracts of 1201 records, and excluded 1138 records. We screened 63 full‐text articles, and excluded 25 studies (26 articles) that did not meet the inclusion criteria or were not relevant (<a href="./references#CD012336-bbs2-0024" title="AldemirM , AgrasK , DehniD , KayigilO . Prospective comparison of two treatment modalities in benign prostatic hyperplasia: alpha-blocker alone vs. alpha-blocker plus anticholinergic combination. Turkiye Klinikleri Tip Bilimleri Dergisi2010;30(2):539-43. ">Aldemir 2010</a>; <a href="./references#CD012336-bbs2-0025" title="AliFM , AlaridyHM , ObaidAA . Role of trospium chloride and tamsulosin therapy for treating patients with symptoms of over-active bladder related to benign prostatic enlargement. International Journal of Research in Pharmaceutical Sciences2020;11(1):650-6. [DOI: doi.org/10.26452/ijrps.v11i1.1871]">Ali 2020</a>; <a href="./references#CD012336-bbs2-0026" title="ChenS , WenH , ZhouB , LiJ . Therapeutic effect of solifenacin combined with tamsulosin on benign prostatic hyperplasia with overactive bladder. International Journal of Clinical and Experimental Medicine2018;11(12):13820-6. ">Chen 2018</a>; <a href="./references#CD012336-bbs2-0027" title="DevaTP , MounikaP , CharanKS , ShabnamS , DhivyaK . Effect of anti-cholinergics with tamsulosin for treating benign prostate hyperplasia patients with an overactive bladder: a clinico-comparative study. International Journal of Medical Research &amp; Health Sciences2017;6(5):7-13. [ISSN No: 2319-5886]">Deva 2017</a>; <a href="./references#CD012336-bbs2-0028" title="DuLH . Efficacy of high dose tamsulosin plus fumaric acid fesoterodine for benign prostatic hyperplasia and the importance of high quality of nursing care [大剂量坦索罗辛与富马酸非索罗定联合治疗良性前列腺增生症的疗效及优质护理的作用]. Evaluation and analysis of drug-use in hospitals of China2015;15(07):909-11. [DOI: 10.14009/j. issn.1672-2124.2015.07.024]">Du 2015</a>; <a href="./references#CD012336-bbs2-0029" title="FangNJ , YuJD , MiuQL , ZhaoFM , SunSB . Tamsulosin treatment tolterodine combined detrusor instability prostatic hyperplasia [坦洛新联合托特罗定治疗逼尿肌不稳定前列腺增生]. China Modern Doctor2012;50(04):84-5. [1673-9701(2012)04-0084-02]">Fang 2012</a>; <a href="./references#CD012336-bbs2-0030" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. Neurourology and Urodynamics2010;21:S152-s154. [www.ics.org/Abstracts/Publish/105/000103.pdf]">Fujihara 2010</a>; <a href="./references#CD012336-bbs2-0031" title="GanW , ZhangSF , JiaHT , XieS , LuoMH , LiYF . Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(4):348-50. [DOI: 10.13263/j.cnki.nja.2011.04.019]">Gan 2011</a>; <a href="./references#CD012336-bbs2-0032" title="GaoZW , XinSY , ZhangJG , RenXQ , ShangYF , ZhangW , et al. Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder. Zhonghua Nan Ke Xue [National Journal of Andrology]2014;20(3):239-43. [DOI: 10.13263/J.CNKI.NJA.2014.03.009]">Gao 2014</a>; <a href="./references#CD012336-bbs2-0033" title="HeWQ . Clinicals study on tolterodine combined with tamsulosin in the treatment of prostatic hyperplasia complicated with overactive bladder [托特罗定联合坦索罗辛治疗前列腺增生合并膀胱过度活动症临床研究]. China Pharmaceuticals2019;28(6):45-7. [DOI: 10.3969/j.issn.1006-4931.2019.06.016]">He 2019</a>; <a href="./references#CD012336-bbs2-0034" title="KosilovK , KuzinaI , KuznetsovV , GainullinaY , KosilovaL , ProkofyevaA , et al. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Aging Male2018;21(2):121-9. [DOI: 10.1080/13685538.2017.1398723]">Kosilov 2018</a>; <a href="./references#CD012336-bbs2-0035" title="LeeSH , ByunSS , LeeSJ , KimKH , LeeJY . Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study. International Urology and Nephrology2014;46(3):523-9. [DOI: 10.1007/s11255-013-0551-7]">Lee 2014</a>; <a href="./references#CD012336-bbs2-0036" title="MalkoçE , AteşF , ŞenkulT , AdayenerC , SoydanH , BaykalKV . Additive role of trospium chloride in the management of men with voiding and storage symptoms. Turkiye Klinikleri Journal of Medical Sciences2012;32(5):1374-80. [DOI: 10.5336/medsci.2012-28431]MalkocE , AtesF , SenkulT , AdayenerC , SoydanH , BaykalK . Role of the addition of trospium chloride to the treatment of patients with both low urinary tract symptoms and overactive bladder. Urology2011;78(3):S412. ">Malkoç 2012</a>; <a href="./references#CD012336-bbs2-0037" title="MaruyamaO , KawachiY , HanazawaK , KoizumiK , YamashitaR , SugimuraS , et al. Naftopidil monotherapy versus naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled study. International Journal of Urology2006;13(10):1280-5. [DOI: 10.1111/j.1442-2042.2006.01538.x]">Maruyama 2006</a>; <a href="./references#CD012336-bbs2-0038" title="NCT02972268. Clinical trial to compare the solifenacin/tamsulosin combination therapy with tamsulosin monotherapy for LUTS due to BPH. clinicaltrials.gov/show/NCT02972268 (first received 23 November 2016). [NCT02972268]">NCT02972268</a>; <a href="./references#CD012336-bbs2-0039" title="QinXY , WangTM . Analysis of efficacy and safety of combination therapy of doxazosin and solifenacin for benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合索利那新治疗良性前列腺增生伴膀胱过度活动症的疗效和安全性分析]. Journal of China Prescription Drug2019;17(10):1-3. [DOI: 10.3969/j.issn.1671-945X.2019.10.002]">Qin 2019</a>; <a href="./references#CD012336-bbs2-0040" title="RovnerES , KrederK , SussmanDO , KaplanSA , CarlssonM , BavendamllT , et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. Journal of Urology2008;180(3):1034-41. [DOI: 10.1016/j.juro.2008.05.050]">Rovner 2008</a>; <a href="./references#CD012336-bbs2-0041" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin but not tamsulosin affects morphometric and functional parameters of the prostate in patients with benign prostate enlargement (BPE) and overactive bladder (OAB). results from a randomized pilot study. Neurourology and Urodynamics2016;35:S79-80. [www.ics.org/Abstracts/Publish/326/000040.pdf]">Sakalis 2016</a>; <a href="./references#CD012336-bbs2-0042" title="TakahashiS , TakedaM , NishizawaO , GotohM , YoshidaM , MasumoriN . The combination therapy of imidafenacin and tamsulosin is effective and safe in benign prostatic hyperplasia patients with overactive bladder; the one year results from addition study. Journal of Urology2013;189(4):e568. [DOI: 10.1016/j.juro.2013.02.2743]">Takahashi 2013</a>; <a href="./references#CD012336-bbs2-0043" title="WangDX . Clinical analysis of tamsulosin combined with solifenacin in the treatment of benign prostatic hyperplasia [坦索罗辛联合索利那新治疗良性前列腺增生的临床分析]. Contemporary Medicine2013;19(28):139. [DOI: 10.3969/j.issn.1009-4393.2013.28.102]">Wang 2013</a>; <a href="./references#CD012336-bbs2-0044" title="XinSQ , RenXQ , ZhangJG , GaoZW , YuanHX , ZhaoH . Efficacy of tamsulosin combined with solifenacin in the treatment of different symptoms of benign prostatic hyperplasia combined with overactive bladder [坦索罗辛联合索利那新在治疗前列腺增生不同症状阶段伴膀胱过度活动症的疗效]. Chinese Journal of Gerontology2016;36(17):4293-5. [DOI: 10. 3969/j.issn.1005-9202.2016.17.079]">Xin 2016</a>; <a href="./references#CD012336-bbs2-0045" title="XuX , ZhangZY , FengQY , HuM , YuanFX . The difference in efficacy and safety of tamsulosin combined with solifenacin and tamsulosin alone in improving lower urinary tract symptoms in patients with benign prostatic hyperplasia [坦索罗辛联合索利那新与单用坦索罗辛对改善前列腺增生症下尿路症状的疗效及安全性的差异]. Northern Pharmacy2015;12(07):129-30. [1672-8351(2015)07-0129-02]">Xu 2015</a>; <a href="./references#CD012336-bbs2-0046" title="YanP , ChenK , ChenC . Efficacy and safety of tamsulosin combined with solifenacin in treatment of mild and moderate benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗轻中度良性前列腺增生伴膀胱过度活动症的疗效及安全性]. Evaluation and Analysis of Drug-Use in Hospitals of China2018;18(09):1205-7. [DOI: 10.14009/j.issn.1672-2124.2018.09.016]">Yan 2018</a>; <a href="./references#CD012336-bbs2-0047" title="YangD . The observation of the effect of tamsulosin joint tolterodine in the treatment of the instability of prostatic hyperplasia and bladder detrusor [坦索罗辛联合托特罗定治疗前列腺增生合并膀胱逼尿肌不稳定的效果观察]. China Health Industry2014;12(22):16-7. [DOI: 10.16659/j.cnki.1672-5654.2014.22.078]">Yang 2014</a>; <a href="./references#CD012336-bbs2-0048" title="ZhaoXF , ZhangYC , PanJB , WangSY , ZhaoZB , SunXF . M-blockers combined with alpha blockers in the treatment of benign prostatic hyperplasia with lower urinary tract symptoms: a randomized controlled trial [M受体阻滞剂与α受体阻滞剂联合治疗前列腺增生伴下尿路症状的随机对照研究]. National Journal of Andrology　2011;17(01):73-5. [DOI: 10.13263/j.cnki.nja.2011.01.020]">Zhao 2011</a>). We included 23 studies (37 articles) in the review (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). The flow of literature through this assessment process is shown in the PRISMA flowchart (<a href="#CD012336-fig-0001">Figure 1</a>). </p> </section> <section id="CD012336-sec-0044"> <h4 class="title">Included studies</h4> <p>Details of the included studies are presented in the <a href="./references#CD012336-sec-0133" title="">Characteristics of included studies</a> table and the baseline characteristics are shown in <a href="#CD012336-tbl-0004">Table 1</a>. We included 23 trials that randomized 6285 men with LUTS due to BPO, published between 2006 and 2018. Of those, 16 were published in English language (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>); six in Chinese language (<a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>); and one in Korean language (<a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>). In addition, we tried to contact each author of the studies to obtain the additional information, but we only received three responses (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>). The additional information is summarized in the survey of trial investigators providing information on included trials (<a href="./appendices#CD012336-sec-0122">Appendix 10</a>). </p> <div class="table" id="CD012336-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of intervention (duration of follow‐up)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Description of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial period</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Ethnic groups (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of disease</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="4" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]"><b>Cai 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + tolterodine ER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>24 weeks (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Men ages ≥ 50 yr; IPSS ≥ 12; QoL score ≥ 3; TPV ≥ 25 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>December 2009 to March 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>100% Chinese</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: tolterodine ER + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: placebo + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]"><b>Cho 2017</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: alfuzosin + imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 45 yr; with LUTS and storage symptoms for &gt; 3 months; IPSS ≥ 12; IPSS question 4 score ≥ 2; TPV &gt; 20 mL; micturitions ≥ 8 per 24 h; 5 mL/s ≤ Qmax ≤ 15 mL/s </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: alfuzosin + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]"><b>He 2012</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 50 yr; IPSS ≥ 8; QoL score ≥ 3; OABSS ≥ 3; Qmax &lt; 15 mL/s; PRV &lt; 60 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>June 2010 to December 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]"><b>Kang 2009</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 50 yr; IPSS ≥ 12; QoL score ≥ 3; TPV ≥ 25 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>May 2007 to April 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="4" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. "><b>Kaplan 2006</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + tolterodine ER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Men ages ≥ 40 yr; IPSS ≥ 12; QoL score ≥ 3; micturition frequency ≥ 8 per 24 h and urgency ≥ 3 per 24 h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>November 2004 to May 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>82.5% white and 17.5% non‐white (black, Asian, other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: tolterodine ER + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: placebo + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]"><b>Kaplan 2009</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 13; PPBC ≥ 3; Qmax ≥ 5 mL/s with volume ≤ 200 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>May 2006 to January 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>83.4% white and 16.6% non‐white (black, other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]"><b>Kaplan 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin OCAS 0.4 mg + solifenacin 6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 8; Bladder Outlet Obstruction Index ≥ 20; Qmax ≤ 12 mL/s with volume ≥ 120 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>June 2007 to August 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>96.4% white and 3.6% non‐white (black, Asian, other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin OCAS 0.4 mg + solifenacin 9 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]"><b>Lee 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: doxazosin GITS + tolterodine ER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 14 (voiding subscore ≥ 8 and storage subscore ≥ 6); QoL ≥ 3; micturition frequency ≥ 8 per 24 h; urgency ≥ 1 per 24 h; TPV ≥ 20 mL; Qmax ≤ 15 mL/s with volume ≥ 125 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: doxazosin GITS + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]"><b>Lee 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin 0.2 mg + solifenacin 5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 8; OABSS ≥ 3; Question 2 of OABSS ≥ 2; TPV ≥ 20 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin 0.2 mg + solifenacin 10 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]"><b>Liu 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages &gt; 50 yr; IPSS &gt; 8; OABSS &gt; 3; Qmax &lt; 5 mL/s; micturition ≥ 8; nocturia ≥ 3 per 24 h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]"><b>MacDiarmid 2008</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + oxybutynin ER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 13 and storage IPSS ≥ 8; Qmax ≥ 8 mL/s with volume ≥ 125 mL; PVR ≤ 150 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>March 2004 to June 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]"><b>Matsukawa 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: silodosin + propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 year (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 50 yr; IPSS ≥ 8; QoL score ≥ 3; OABSS ≥ 3; urinary urgency episodes ≥ 1 per week; TPV ≥ 25 mL; Qmax &lt; 15 mL/s with volume ≥ 100 mL; PVR &lt; 150 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>August 2011 and June 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: silodosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]"><b>Memon 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: alfuzosin + tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 40 yr; IPSS 15–30; Qmax &lt; 5 mL/s with volume ≥ 100 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>May 2012 and September 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: alfuzosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]"><b>Nishizawa 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin 0.2 mg + propiverine 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Men ages ≥ 50 yr; IPSS ≥ 8 with urgency item score ≥ 1; QoL ≥ 2; Qmax &lt; 15 mL/s with volume ≥ 150 mL; 8 micturitions and 1 urgency per 24 h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>October 2004 to September 2008.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin 0.2 mg + propiverine 20 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin, daily</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]"><b>Sakalis 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin OCAS + solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26 weeks (26 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 50 yr; IPSS storage subscore ≥ voiding subscore and score ≥ 3 in the IPSS urgency question; ≥ 3 urgency episodes per 24 h; prostate volume ≥ 30 mL; Qmax ≥ 10 mL/s; PVR ≤ 100 mL; PSA ≤ 4 ng/mL. Participants with suspicious rectal exam or PSA values 4–10 ng/mL (or both) were included only after negative prostate biopsy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>October 2013 to June 2015.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Greece</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100% white</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin OCAS</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]"><b>Sener 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: propiverine + terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 year (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 40 yr; IPSS &gt; 12; micturition frequency &gt; 8 per 24 h; urgency episodes &gt; 3 per 24 h; PSA &lt; 2.5 ng/mL; having documented detrusor pressure &gt; 10 cmH<sub>2</sub>O in urodynamic studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>May 2009 to November 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo + terazosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]"><b>Shen 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: terazosin+ tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 60 yr; IPSS ≥ 8; TPV &lt; 60 mL; Qmax &lt; 15 mL/s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>January 2010 to October 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: terazosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="4" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]"><b>Van Kerrebroeck 2013b</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin OCAS 0.4 mg + solifenacin 6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 13; Qmax 4–12 mL/s with volume ≥ 120 mL; micturition frequency ≥ 8 per 24 h; urgency episodes ≥ 2 per 24 h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>January 2010 to March 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>99.2% white and 0.8% non‐white (black, Asian, other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin OCAS 0.4 mg + solifenacin 9 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin OCAS + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: placebo + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="8" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. "><b>Van Kerrebroeck 2013c</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: solifenacin 3 mg + tamsulosin OCAS 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 13; Qmax 4–15 mL/s with volume ≥ 120 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>99.6% white and 0.4% non‐white (black, other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: solifenacin 6 mg + tamsulosin OCAS 0.4 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: solifenacin 9 mg + tamsulosin OCAS 0.4 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: solifenacin 3 mg + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: solifenacin 6 mg + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C4: solifenacin 9 mg + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C5: tamsulosin OCAS 0.4 mg + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]"><b>Wang 2015</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin 0.2 mg + fesoterodine 4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 50 yr; IPSS &gt; 8 and storage IPSS ≥ 6; QoL score ≥ 3; Qmax &lt; 15 mL/s with volume ≥ 200 mL; PRV &lt; 60 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>January 2013 to September 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin 0.2 mg</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]"><b>Wang 2017</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin 0.2 mg + solifenacin 5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men; IPSS ≥ 8; OABSS ≥ 3; mean urination frequency ≥ 8 times/day; nocturia episodes ≥ 2; urine volume ≥ 200 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>April 2014 to December 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin 0.2 mg</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]"><b>Wu 2009</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin 0.2 mg + tolterodine 2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages &gt; 50 yr; IPSS &gt; 8 and storage IPSS ≥ 6; QoL score ≥ 3; Qmax &lt; 15 mL/s with volume ≥ 200 mL; PRV &lt; 60 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>June 2006 to June 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin 0.2 mg</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]"><b>Yu 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: doxazosin 4 mg + tolterodine 2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 50 yr; IPSS ≥ 12; QoL score ≥ 3; complain of urgency and frequency with volume &lt; 300 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>October 2007 to December 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: doxazosin 4 mg</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>— denotes not reported.</p> <p>C: comparator; I: intervention; ER: extended release; GITS: gastrointestinal therapeutic system; h: hour; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; OABSS: Overactive Bladder Symptom Score; OCAS: oral controlled absorption system; PPBC: Patient Perception of Bladder Condition; PRV: postvoid residual; Qmax: maximum flow rate; QoL: quality of life; s: second; SD: standard deviation; TPV: total prostate volume; yr: year. </p> </div> </div> <section id="CD012336-sec-0045"> <h5 class="title">Design</h5> <p>All the 23 studies were parallel RCTs. Eleven studies were multi‐centered (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>), and 12 were single‐centered (<a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). In terms of location, eight were conducted in China (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>), four in South Korea (<a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>), four in the USA (<a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>), three in Europe (<a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>), two in Japan (<a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>), one in Turkey (<a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>), and one in Pakistan (<a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>). </p> </section> <section id="CD012336-sec-0046"> <h5 class="title">Participants</h5> <p>All participants were over the age of 40 years. <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a> studied the youngest population (mean 54.4 years, SD 6), while <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a> studied the oldest one (mean 73.9 years, SD 5). The ethnic composition of participants were described in <a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a> (100% Chinese), <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a> (82.5% white and 17.5% non‐white (black, Asian, other)), <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a> (83.4% white and 16.6% non‐white (black, other)), <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a> (96.4% white and 3.6% non‐white (black, Asian, other)), <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a> (90.2% white and 9.8% non‐white (black, Asian, other)), <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a> (100% white Caucasians), <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a> (99.2% white and 0.8% non‐white (black, Asian, other)), and <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a> (99.6% white and 0.4% non‐white (black, other)). </p> <p>In terms of the severity of LUTS by IPSS, <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a> focused on the men with lower severity (mean 13, SD 6.4), whereas <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a> centered on men with greater severity (mean 29, SD 2). The baseline prostate volume was reported in <a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a> (mean 41.8 mL, SD 16.1), <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a> (mean 36.0 mL, range 20 to 92.4), <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a> (mean 31.1 mL, SD 8.8), <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a> (mean 34.5 mL, SD 4), <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a> (mean 45.7 mL, SD 17.3), <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a> (mean 28.9 mL, SD 26.7), and <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a> (mean 50.8 mL, SD 23.9). </p> <p>Several trials failed to report some baseline characteristics. <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a> did not report age of participants. Fifteen studies did not report ethnicity of participants (<a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). Fifteen studies did not report prostate volume (<a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). </p> </section> <section id="CD012336-sec-0047"> <h5 class="title">Interventions</h5> <p>The details of interventions are presented in <a href="#CD012336-tbl-0005">Table 2</a>. All studies used combination therapy with anticholinergics and alpha‐blockers as the experimental intervention; nine trials used solifenacin combined with tamsulosin (<a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>); seven trials used tolterodine combined with tamsulosin (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>), doxazosin (<a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>), alfuzosin (<a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>), or terazosin (<a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>); four trials used propiverine combined with tamsulosin (<a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>), silodosin (<a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>), or terazosin (<a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>); one trial used imidafenacin with alfuzosin (<a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>); the remaining trials used oxybutynin (<a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>) or fesoterodine (<a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>) with tamsulosin. </p> <div class="table" id="CD012336-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Description of Interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) (route, frequency, total dose/day)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) appropriate as applied in a clinical practice setting<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator(s) (route, frequency, total dose/day)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator(s) appropriate as applied in a clinical practice setting<sup>a</sup> </b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]"><b>Cai 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + tolterodine ER (orally, once a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; tolterodine ER 4 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; tolterodine ER, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: tolterodine ER (orally, once a day, total 4 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tolterodine ER 4 mg, orally, once a day</p> <p>Provision for contraindications: tolterodine ER, closed‐angle glaucoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: placebo + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/CPS</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]"><b>Cho 2017</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: alfuzosin (orally, once a day, total 10 mg/day) + imidafenacin (orally, twice a day, total 0.2 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: alfuzosin 10 mg, orally, once a day; imidafenacin 0.1 mg, orally, twice a day, </p> <p>Provision for contraindications: alfuzosin, postural hypotension; imidafenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: alfuzosin (orally, once a day, total 10 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: alfuzosin 10 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]"><b>He 2012</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + solifenacin (orally, once a day, total 5 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]"><b>Kang 2009</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + propiverine (orally, once a day, total 10 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; propiverine 20 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; propiverine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. "><b>Kaplan 2006</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.4 mg/day) + tolterodine ER (orally, once a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; tolterodine ER 4 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; tolterodine ER, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.4 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: tolterodine ER (orally, once a day, total 4 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tolterodine ER 4 mg, orally, once a day</p> <p>Provision for contraindications: tolterodine ER, closed‐angle glaucoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: placebo + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/CPS</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]"><b>Kaplan 2009</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.4 mg/day) + solifenacin (orally, once a day, total 5 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.5 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]"><b>Kaplan 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin OCAS and solifenacin 6 mg (orally, once a day, total tamsulosin 0.4 mg/day and solifenacin 6 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin OCAS and solifenacin 6 mg (orally, once a day, total tamsulosin 0.4 mg/day and solifenacin 9 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]"><b>Lee 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: doxazosin GITS (orally, once a day, total doxazosin 4 mg/day) + tolterodine ER (orally, once a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: doxazosin 4 mg, orally, once a day; tolterodine ER 4 mg, orally, once a day </p> <p>Provision for contraindications: doxazosin, postural hypotension; tolterodine ER, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: doxazosin gastrointestinal therapeutic system (GITS) (orally, once a day, total doxazosin 4 mg/day) + placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: doxazosin 4 mg, orally, once a day</p> <p>Provision for contraindications: doxazosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]"><b>Lee 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + solifenacin (orally, once a day, total 5 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin (orally, once a day, total 0.2 mg/day) + solifenacin (orally, once a day, total 10 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]"><b>Liu 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + solifenacin (orally, once a day, total 5 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]"><b>MacDiarmid 2008</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.4 mg/day) + oxybutynin ER (orally, once a day, total 10 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; oxybutynin ER 10 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; oxybutynin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (0.4 mg, once a day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]"><b>Matsukawa 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: silodosin (orally, once a day, total 8 mg/day) + propiverine (orally, once a day, total 20 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: silodosin 8 mg, orally, once a day; propiverine 20 mg, orally, once a day </p> <p>Provision for contraindications: silodosin, postural hypotension; propiverine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: silodosin (orally, once a day, total 8 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: silodosin 8 mg, orally, once a day</p> <p>Provision for contraindications: silodosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]"><b>Memon 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: alfuzosin (orally, once a day, total 10 mg/day) + tolterodine (orally, 2 mg twice a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: alfuzosin 10 mg, orally, once a day; tolterodine 2 mg, orally, twice a day </p> <p>Provision for contraindications: alfuzosin, postural hypotension; tolterodine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: alfuzosin 10 mg, once a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: alfuzosin 10 mg, orally, once a day</p> <p>Provision for contraindications: alfuzosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]"><b>Nishizawa 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin 0.2 mg (orally, once a day, total 0.2 mg/day) + propiverine (orally, once a day, total 10 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; propiverine 20 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; propiverine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>C1: tamsulosin 0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin 0.2 mg (orally, once a day, total 0.2 mg/day) + propiverine (orally, once a day, total 20 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; propiverine 20 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; propiverine, closed‐angle glaucoma </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]"><b>Sakalis 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin OCAS (orally, once a day, total 0.4 mg/day) and solifenacin (orally, once a day, total 5 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin oral controlled absorption system (TOCAS) (orally, once a day, total 0.4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]"><b>Sener 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: terazosin 2 mg (orally, once a day, total 2 mg/day) + propiverine (orally, once a day, total 15 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: terazosin 2 mg, orally, once a day; propiverine 20 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; propiverine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: terazosin (orally, once a day, total 2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: terazosin 2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]"><b>Shen 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: terazosin 2 mg (orally, once a day, total 2 mg/day) + tolterodine (orally, 2 mg twice a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: terazosin 2 mg, orally, once a day; tolterodine 2 mg, orally, twice a day </p> <p>Provision for contraindications: terazosin, postural hypotension; tolterodine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: terazosin (orally, once a day, total 2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: terazosin 2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]"><b>Van Kerrebroeck 2013b</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin OCAS (orally, once a day, total 0.4 mg/day) and solifenacin (orally, once a day, total 6 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin oral controlled absorption system (TOCAS) (orally, once a day, total 0.4 mg/day) + placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin OCAS (orally, once a day, total 0.4 mg/day) and solifenacin (orally, once a day, total 9 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: placebo + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/CPS</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="5" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. "><b>Van Kerrebroeck 2013c</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: solifenacin (orally, once a day, total 3 mg/day) + tamsulosin OCAS (orally, once a day, total 0.4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: solifenacin (orally, once a day, total 6 mg/day) + tamsulosin OCAS (orally, once a day, total 0.4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: solifenacin (orally, once a day, total 3 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: solifenacin 5 mg, orally, once a day</p> <p>Provision for contraindications: solifenacin, closed‐angle glaucoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I3: solifenacin (orally, once a day, total 9 mg/day) + tamsulosin OCAS (orally, once a day, total 0.4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: solifenacin (orally, once a day, total 6 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: solifenacin 5 mg, orally, once a day</p> <p>Provision for contraindications: solifenacin, closed‐angle glaucoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C4: solifenacin (orally, once a day, total 9 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: solifenacin 5 mg, orally, once a day</p> <p>Provision for contraindications: solifenacin, closed‐angle glaucoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C5: tamsulosin OCAS (orally, once a day, total 0.4 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]"><b>Wang 2015</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + fesoterodine (orally, once a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; fesoterodine 4 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; fesoterodine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]"><b>Wang 2017</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + solifenacin (orally, once a day, total 5 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]"><b>Wu 2009</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + tolterodine (orally, 2 mg once a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; tolterodine 2 mg, orally, twice a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; tolterodine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]"><b>Yu 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: doxazosin (orally, once a day, total doxazosin 4 mg/day) + tolterodine (orally, 2 mg twice a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: doxazosin 4 mg, orally, once a day; tolterodine 2 mg, orally, twice a day </p> <p>Provision for contraindications: doxazosin, postural hypotension; tolterodine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: doxazosin (orally, once a day, total doxazosin 4 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: doxazosin 4 mg, orally, once a day</p> <p>Provision for contraindications: doxazosin, postural hypotension</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>The term 'clinical practice setting' refers to the specification of the intervention/comparator as used in the course of a standard medical treatment (such as dose, dose escalation, dosing scheme, provision for contraindications, and other important features). </p> <p>C: comparator; I: intervention; N/CPS: no specification of clinical practice setting possible; ER: extended release; GITS: gastrointestinal therapeutic system; OCAS: oral controlled absorption system. </p> </div> </div> <p>Five trials used placebo was used the comparator intervention (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). Alpha‐blocker and anticholinergic in comparator group were the same in the experimental group to establish fair comparisons. </p> <p>Duration of treatment ranged from 12 weeks to one year. Of the 23 included studies, 19 provided 12 weeks' treatment (<a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). Two performed 24 weeks' (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>) and 26 weeks' (<a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>) treatment. Two studies conducted one year' treatment (<a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>). </p> </section> <section id="CD012336-sec-0048"> <h5 class="title">Comparisons</h5> <p>Five trials compared combination therapy to placebo (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>), and 22 trials conducted the comparison between combination therapy and alpha‐blockers (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). Three studies compared combination therapy and anticholinergics (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). Seven trials had one or more comparisons (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). </p> </section> <section id="CD012336-sec-0049"> <h5 class="title">Outcomes</h5> <p>For primary outcomes, all the 23 included studies reported urologic symptom score assessed by IPSS, and 18 reported QoL assessed using IPSS‐QoL score (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). Twenty‐two studies reported adverse events (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). Of these, nine studies reported the overall adverse events (<a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>), and the other 13 studies only reported the individual adverse events (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). After contacting the authors, four confirmed the overall adverse events (<a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). </p> <p>For secondary outcomes, only <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a> reported AUR as one of outcomes and another 19 studies reported it within adverse events (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). Only four studies reported surgical intervention, which was described in adverse events (<a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). </p> <p>All studies reported short‐term outcomes only.</p> </section> <section id="CD012336-sec-0050"> <h5 class="title">Funding and conflicts of interest</h5> <p>Seven studies specified funding sources: <a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a> – Chinese Capital Medical Development Science Fund; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a> – Research Grant from Pfizer Inc.; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a> – Research Grant from Astellas Pharma US Inc.; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a> – Astellas Pharmaceuticals research fund; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a> – McNeil Consumer and Specialty Pharmaceuticals; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a> – Research Grant from Astellas Pharma Europe B.V.; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a> – Research Grant from Astellas Pharma Europe B.V. Eleven studies did not mention funding source (<a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>), and the remaining trials reported no funding source (<a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>). </p> <p>Seven study declared conflicts of interest. <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a> declared three researchers were employees of pharmaceutical companies and two other researchers received fees from pharmaceutical companies; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a> declared four researchers received fees from pharmaceutical companies; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a> declared three researchers were employees of pharmaceutical companies and another researcher received fees from pharmaceutical companies; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a> declared three researchers received fees from pharmaceutical companies; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a> declared two researchers were funded by grant from the EU and Greek national resources; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a> declared three researchers were employees of pharmaceutical companies and four other researchers received fees from pharmaceutical companies; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a> declared three researchers were employees of pharmaceutical companies and four other researchers received fees from pharmaceutical companies. The other 16 studies declared no conflict of interest (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). </p> </section> </section> <section id="CD012336-sec-0051"> <h4 class="title">Excluded studies</h4> <p>We excluded 25 studies and presented the details in the <a href="./references#CD012336-sec-0134" title="">Characteristics of excluded studies</a> table. Seven studies were not RCTs (<a href="./references#CD012336-bbs2-0027" title="DevaTP , MounikaP , CharanKS , ShabnamS , DhivyaK . Effect of anti-cholinergics with tamsulosin for treating benign prostate hyperplasia patients with an overactive bladder: a clinico-comparative study. International Journal of Medical Research &amp; Health Sciences2017;6(5):7-13. [ISSN No: 2319-5886]">Deva 2017</a>; <a href="./references#CD012336-bbs2-0029" title="FangNJ , YuJD , MiuQL , ZhaoFM , SunSB . Tamsulosin treatment tolterodine combined detrusor instability prostatic hyperplasia [坦洛新联合托特罗定治疗逼尿肌不稳定前列腺增生]. China Modern Doctor2012;50(04):84-5. [1673-9701(2012)04-0084-02]">Fang 2012</a>; <a href="./references#CD012336-bbs2-0031" title="GanW , ZhangSF , JiaHT , XieS , LuoMH , LiYF . Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(4):348-50. [DOI: 10.13263/j.cnki.nja.2011.04.019]">Gan 2011</a>; <a href="./references#CD012336-bbs2-0032" title="GaoZW , XinSY , ZhangJG , RenXQ , ShangYF , ZhangW , et al. Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder. Zhonghua Nan Ke Xue [National Journal of Andrology]2014;20(3):239-43. [DOI: 10.13263/J.CNKI.NJA.2014.03.009]">Gao 2014</a>; <a href="./references#CD012336-bbs2-0037" title="MaruyamaO , KawachiY , HanazawaK , KoizumiK , YamashitaR , SugimuraS , et al. Naftopidil monotherapy versus naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled study. International Journal of Urology2006;13(10):1280-5. [DOI: 10.1111/j.1442-2042.2006.01538.x]">Maruyama 2006</a>; <a href="./references#CD012336-bbs2-0043" title="WangDX . Clinical analysis of tamsulosin combined with solifenacin in the treatment of benign prostatic hyperplasia [坦索罗辛联合索利那新治疗良性前列腺增生的临床分析]. Contemporary Medicine2013;19(28):139. [DOI: 10.3969/j.issn.1009-4393.2013.28.102]">Wang 2013</a>; <a href="./references#CD012336-bbs2-0044" title="XinSQ , RenXQ , ZhangJG , GaoZW , YuanHX , ZhaoH . Efficacy of tamsulosin combined with solifenacin in the treatment of different symptoms of benign prostatic hyperplasia combined with overactive bladder [坦索罗辛联合索利那新在治疗前列腺增生不同症状阶段伴膀胱过度活动症的疗效]. Chinese Journal of Gerontology2016;36(17):4293-5. [DOI: 10. 3969/j.issn.1005-9202.2016.17.079]">Xin 2016</a>); two studies used combination therapy in both study arms (<a href="./references#CD012336-bbs2-0028" title="DuLH . Efficacy of high dose tamsulosin plus fumaric acid fesoterodine for benign prostatic hyperplasia and the importance of high quality of nursing care [大剂量坦索罗辛与富马酸非索罗定联合治疗良性前列腺增生症的疗效及优质护理的作用]. Evaluation and analysis of drug-use in hospitals of China2015;15(07):909-11. [DOI: 10.14009/j. issn.1672-2124.2015.07.024]">Du 2015</a>; <a href="./references#CD012336-bbs2-0035" title="LeeSH , ByunSS , LeeSJ , KimKH , LeeJY . Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study. International Urology and Nephrology2014;46(3):523-9. [DOI: 10.1007/s11255-013-0551-7]">Lee 2014</a>); one study treated both arms using alpha‐blockers monotherapy (<a href="./references#CD012336-bbs2-0030" title="FujiharaA , UkimuraO , IwataT , UshijimaS , ToiyamaD , SuzukiK , et al. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder. Neurourology and Urodynamics2010;21:S152-s154. [www.ics.org/Abstracts/Publish/105/000103.pdf]">Fujihara 2010</a>); one study did not have a control arm (<a href="./references#CD012336-bbs2-0024" title="AldemirM , AgrasK , DehniD , KayigilO . Prospective comparison of two treatment modalities in benign prostatic hyperplasia: alpha-blocker alone vs. alpha-blocker plus anticholinergic combination. Turkiye Klinikleri Tip Bilimleri Dergisi2010;30(2):539-43. ">Aldemir 2010</a>); six studies conducted four or eight weeks' follow‐up, which did not meet our criteria of follow‐up (<a href="./references#CD012336-bbs2-0033" title="HeWQ . Clinicals study on tolterodine combined with tamsulosin in the treatment of prostatic hyperplasia complicated with overactive bladder [托特罗定联合坦索罗辛治疗前列腺增生合并膀胱过度活动症临床研究]. China Pharmaceuticals2019;28(6):45-7. [DOI: 10.3969/j.issn.1006-4931.2019.06.016]">He 2019</a>; <a href="./references#CD012336-bbs2-0034" title="KosilovK , KuzinaI , KuznetsovV , GainullinaY , KosilovaL , ProkofyevaA , et al. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Aging Male2018;21(2):121-9. [DOI: 10.1080/13685538.2017.1398723]">Kosilov 2018</a>; <a href="./references#CD012336-bbs2-0039" title="QinXY , WangTM . Analysis of efficacy and safety of combination therapy of doxazosin and solifenacin for benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合索利那新治疗良性前列腺增生伴膀胱过度活动症的疗效和安全性分析]. Journal of China Prescription Drug2019;17(10):1-3. [DOI: 10.3969/j.issn.1671-945X.2019.10.002]">Qin 2019</a>; <a href="./references#CD012336-bbs2-0045" title="XuX , ZhangZY , FengQY , HuM , YuanFX . The difference in efficacy and safety of tamsulosin combined with solifenacin and tamsulosin alone in improving lower urinary tract symptoms in patients with benign prostatic hyperplasia [坦索罗辛联合索利那新与单用坦索罗辛对改善前列腺增生症下尿路症状的疗效及安全性的差异]. Northern Pharmacy2015;12(07):129-30. [1672-8351(2015)07-0129-02]">Xu 2015</a>; <a href="./references#CD012336-bbs2-0047" title="YangD . The observation of the effect of tamsulosin joint tolterodine in the treatment of the instability of prostatic hyperplasia and bladder detrusor [坦索罗辛联合托特罗定治疗前列腺增生合并膀胱逼尿肌不稳定的效果观察]. China Health Industry2014;12(22):16-7. [DOI: 10.16659/j.cnki.1672-5654.2014.22.078]">Yang 2014</a>; <a href="./references#CD012336-bbs2-0048" title="ZhaoXF , ZhangYC , PanJB , WangSY , ZhaoZB , SunXF . M-blockers combined with alpha blockers in the treatment of benign prostatic hyperplasia with lower urinary tract symptoms: a randomized controlled trial [M受体阻滞剂与α受体阻滞剂联合治疗前列腺增生伴下尿路症状的随机对照研究]. National Journal of Andrology　2011;17(01):73-5. [DOI: 10.13263/j.cnki.nja.2011.01.020]">Zhao 2011</a>); one study did not meet our criteria of outcomes (<a href="./references#CD012336-bbs2-0040" title="RovnerES , KrederK , SussmanDO , KaplanSA , CarlssonM , BavendamllT , et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. Journal of Urology2008;180(3):1034-41. [DOI: 10.1016/j.juro.2008.05.050]">Rovner 2008</a>), and the population from five other studies did not meet criteria of our review (<a href="./references#CD012336-bbs2-0026" title="ChenS , WenH , ZhouB , LiJ . Therapeutic effect of solifenacin combined with tamsulosin on benign prostatic hyperplasia with overactive bladder. International Journal of Clinical and Experimental Medicine2018;11(12):13820-6. ">Chen 2018</a>; <a href="./references#CD012336-bbs2-0036" title="MalkoçE , AteşF , ŞenkulT , AdayenerC , SoydanH , BaykalKV . Additive role of trospium chloride in the management of men with voiding and storage symptoms. Turkiye Klinikleri Journal of Medical Sciences2012;32(5):1374-80. [DOI: 10.5336/medsci.2012-28431]MalkocE , AtesF , SenkulT , AdayenerC , SoydanH , BaykalK . Role of the addition of trospium chloride to the treatment of patients with both low urinary tract symptoms and overactive bladder. Urology2011;78(3):S412. ">Malkoç 2012</a>; <a href="./references#CD012336-bbs2-0041" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin but not tamsulosin affects morphometric and functional parameters of the prostate in patients with benign prostate enlargement (BPE) and overactive bladder (OAB). results from a randomized pilot study. Neurourology and Urodynamics2016;35:S79-80. [www.ics.org/Abstracts/Publish/326/000040.pdf]">Sakalis 2016</a>; <a href="./references#CD012336-bbs2-0042" title="TakahashiS , TakedaM , NishizawaO , GotohM , YoshidaM , MasumoriN . The combination therapy of imidafenacin and tamsulosin is effective and safe in benign prostatic hyperplasia patients with overactive bladder; the one year results from addition study. Journal of Urology2013;189(4):e568. [DOI: 10.1016/j.juro.2013.02.2743]">Takahashi 2013</a>; <a href="./references#CD012336-bbs2-0046" title="YanP , ChenK , ChenC . Efficacy and safety of tamsulosin combined with solifenacin in treatment of mild and moderate benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗轻中度良性前列腺增生伴膀胱过度活动症的疗效及安全性]. Evaluation and Analysis of Drug-Use in Hospitals of China2018;18(09):1205-7. [DOI: 10.14009/j.issn.1672-2124.2018.09.016]">Yan 2018</a>). In addition, two studies did not provide available data for this review (<a href="./references#CD012336-bbs2-0025" title="AliFM , AlaridyHM , ObaidAA . Role of trospium chloride and tamsulosin therapy for treating patients with symptoms of over-active bladder related to benign prostatic enlargement. International Journal of Research in Pharmaceutical Sciences2020;11(1):650-6. [DOI: doi.org/10.26452/ijrps.v11i1.1871]">Ali 2020</a>; <a href="./references#CD012336-bbs2-0038" title="NCT02972268. Clinical trial to compare the solifenacin/tamsulosin combination therapy with tamsulosin monotherapy for LUTS due to BPH. clinicaltrials.gov/show/NCT02972268 (first received 23 November 2016). [NCT02972268]">NCT02972268</a>). </p> <section id="CD012336-sec-0052"> <h5 class="title">Studies awaiting classification</h5> <p>We found no studies awaiting classification.</p> </section> <section id="CD012336-sec-0053"> <h5 class="title">Ongoing trials</h5> <p>We found no ongoing trials.</p> </section> </section> </section> <section id="CD012336-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>We extracted the methodological details of the studies from the published data and presented details in the <a href="./references#CD012336-sec-0133" title="">Characteristics of included studies</a> table. We presented the summary of judgment about risk of bias in <a href="#CD012336-fig-0002">Figure 2</a> and <a href="#CD012336-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012336-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD012336-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012336-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD012336-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012336-sec-0055"> <h4 class="title">Allocation</h4> <section id="CD012336-sec-0056"> <h5 class="title">Random sequence generation</h5> <p>Eight studies reported adequate methodological details for sequence generation and were at low risk of bias (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>). The other 15 included studies did not provide sufficient information for the method of sequence generation and were at unclear risk of bias (<a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). </p> </section> <section id="CD012336-sec-0057"> <h5 class="title">Allocation concealment</h5> <p>Three studies reported the specific method for allocation concealment and were at low risk of bias (<a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>), and other 20 included studies did not provide sufficient information to allow an assessment and at unclear risk of bias (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). </p> </section> </section> <section id="CD012336-sec-0058"> <h4 class="title">Blinding</h4> <section id="CD012336-sec-0059"> <h5 class="title">Blinding of participants and personnel</h5> <p>We considered 13 studies at high risk of bias for blinding participants and personnel, since these studies were open‐label and all outcomes are susceptible to bias (<a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). Two studies provided sufficient details for blinding performance (<a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>) and eight were placebo‐controlled studies (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>), which were at low risk of bias. </p> </section> <section id="CD012336-sec-0060"> <h5 class="title">Blinding of outcome assessment</h5> <p>For subjective outcomes, 13 studies were at high risk of bias since they were open‐label (<a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>), and three studies were at low risk of bias since sufficient information was provided for the blinding of assessor (<a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>). In the other seven studies, although blinding of outcome assessment was not reported, we considered them at low risk of bias since they were placebo‐controlled trials (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). For objective outcomes, all 23 included studies were at low risk of bias since these outcomes are likely not affected by lack of blinding. </p> </section> </section> <section id="CD012336-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>For urologic symptoms scores and QoL assessed by IPSS questionnaire, we considered 17 studies at low risk of bias since less than 10% of randomized participants were not included in final analysis (<a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). Three studies were at high risk of bias since more than 20% of randomized participants were not involved in analysis (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>), and three other studies were at unclear risk of bias because the percentage of randomized participants who were not included in analysis were moderate (10% to 20%) (<a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>). In terms of adverse events, AUR, and surgical intervention, we classified 21 studies at low risk of bias since almost all randomized participants were included in analysis in these studies (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). We considered two studies at unclear risk of bias because these outcomes were not reported in the study (<a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>). </p> </section> <section id="CD012336-sec-0062"> <h4 class="title">Selective reporting</h4> <p>We judged six studies at low risk of bias since they were performed as planned in the protocol (<a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>), and one study at high risk of bias as some outcomes proposed in protocol were not reported (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>). Other 16 studies were at unclear risk of bias since there was no protocol available (<a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). </p> </section> <section id="CD012336-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>The other potential sources of bias we considered in the review included: Was the trial stopped early due to some data‐dependent process? Was there extreme baseline imbalance? </p> <p>We identified no other potential sources of bias in the included studies.</p> </section> </section> <section id="CD012336-sec-0064"> <h3 class="title" id="CD012336-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD012336-tbl-0001"><b>Summary of findings 1</b> Combination therapy versus placebo for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</a>; <a href="./full#CD012336-tbl-0002"><b>Summary of findings 2</b> Combination therapy versus alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</a>; <a href="./full#CD012336-tbl-0003"><b>Summary of findings 3</b> Combination therapy versus anticholinergics for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</a> </p> <section id="CD012336-sec-0065"> <h4 class="title">1. Combination therapy versus placebo (short term)</h4> <p>We included five studies in this comparison (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). </p> <p>See <a href="./full#CD012336-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD012336-sec-0066"> <h5 class="title">1.1 Primary outcomes</h5> <section id="CD012336-sec-0067"> <h6 class="title">1.1.1 Urologic symptom scores</h6> <p>We included four studies with 1792 participants (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). Combination therapy may result in little or no difference in urologic symptom scores (MD –2.73, 95% CI –5.55 to 0.08; I² = 94%; <a href="./references#CD012336-fig-0004" title="">Analysis 1.1</a>). We rated the certainty of evidence as low, downgrading for study limitations and imprecision. </p> </section> <section id="CD012336-sec-0068"> <h6 class="title">1.1.2 Quality of life</h6> <p>We included two studies with 991 participants (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>). We are very uncertain about the effect of combination therapy on QoL (MD –0.97, 95% CI –2.11 to 0.16; I² = 96%; <a href="./references#CD012336-fig-0005" title="">Analysis 1.2</a>). We rated the certainty of evidence as very low, downgrading for study limitations, inconsistency, and imprecision. </p> </section> <section id="CD012336-sec-0069"> <h6 class="title">1.1.3 Adverse events</h6> <p>We included three studies with 1848 participants (<a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). Combination therapy likely increases adverse events (RR 1.24, 95% CI 1.04 to 1.47; I² = 0%; <a href="./references#CD012336-fig-0006" title="">Analysis 1.3</a>); this corresponded to 61 more adverse events (95% CI 10 more to 119 more) per 1000 participants treated with combination therapy. We rated the certainty of evidence as moderate, downgrading for imprecision. </p> </section> </section> <section id="CD012336-sec-0070"> <h5 class="title">1.2 Secondary outcomes</h5> <section id="CD012336-sec-0071"> <h6 class="title">1.2.1 Acute urinary retention</h6> <p>We included five studies with 2369 participants (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]">Kaplan 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). We are very uncertain about the effect of combination therapy on AUR (RR 1.94, 95% CI 0.41 to 9.08; I² = 0%; <a href="./references#CD012336-fig-0007" title="">Analysis 1.4</a>). We rated the certainty of evidence as very low, downgrading for serious study limitations and very serious imprecision. </p> </section> <section id="CD012336-sec-0072"> <h6 class="title">1.2.2 Surgical intervention</h6> <p>None of the studies reported data on number of men with a need of surgical intervention.</p> </section> </section> <section id="CD012336-sec-0073"> <h5 class="title">1.3 Subgroup analysis</h5> <p>We were unable to perform any of the planned secondary analyses due to lack of relevant data. </p> </section> <section id="CD012336-sec-0074"> <h5 class="title">1.4 Sensitivity analysis</h5> <p>We rated all included studies at low risk of performance and detection bias, therefore the sensitivity analyses were identical with main analyses. </p> </section> </section> <section id="CD012336-sec-0075"> <h4 class="title">2. Combination therapy versus alpha‐blockers (short term)</h4> <p>We included 22 studies for this comparison (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). </p> <p>See <a href="./full#CD012336-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD012336-sec-0076"> <h5 class="title">2.1 Primary outcomes</h5> <section id="CD012336-sec-0077"> <h6 class="title">2.1.1 Urologic symptom scores</h6> <p>We included 19 studies with 3631 participants (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]">Memon 2014</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). We are very uncertain about the effect of combination therapy on urologic symptom scores (MD –2.04, 95% CI –3.56 to –0.52; I² = 97%; <a href="./references#CD012336-fig-0008" title="">Analysis 2.1</a>). We rated the certainty of evidence as very low, downgrading for study limitations, inconsistency, and imprecision. </p> </section> <section id="CD012336-sec-0078"> <h6 class="title">2.1.2 Quality of life</h6> <p>We included 15 studies with 2687 participants (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). We are very uncertain about the effect of combination therapy on QoL (MD –0.71, 95% CI –1.03 to –0.38; I² = 95%; <a href="./references#CD012336-fig-0009" title="">Analysis 2.2</a>). We rated the certainty of evidence as very low, downgrading for study limitations, inconsistency, and imprecision. </p> </section> <section id="CD012336-sec-0079"> <h6 class="title">2.1.3 Adverse events</h6> <p>We included 12 studies with 3561 participants (<a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]">He 2012</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]">Wang 2015</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). Combination therapy may result in little or no difference in adverse event rate (RR 1.10, 95% CI 0.90 to 1.34; I² = 40%; <a href="./references#CD012336-fig-0010" title="">Analysis 2.3</a>); this corresponded to 23 more adverse events (95% CI 23 fewer to 78 more) per 1000 participants treated with combination therapy. We rated the certainty of evidence as low, downgrading for study limitations and imprecision. </p> </section> </section> <section id="CD012336-sec-0080"> <h5 class="title">2.2 Secondary outcomes</h5> <section id="CD012336-sec-0081"> <h6 class="title">2.2.1 Acute urinary retention</h6> <p>We included 19 studies with 4669 participants (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]">Lee 2016</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]">Matsukawa 2016</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]">Shen 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>; <a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]">Wu 2009</a>; <a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]">Wang 2017</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). Combination therapy may result in little to no difference in AUR (RR 2.03, 95% CI 0.97 to 4.23; I² = 0%; <a href="./references#CD012336-fig-0011" title="">Analysis 2.4</a>); this corresponded to 4 more AUR (95% CI 0 to 12 more) per 1000 participants treated with combination therapy. We rated the certainty of evidence as low, downgrading for study limitations and imprecision. </p> </section> <section id="CD012336-sec-0082"> <h6 class="title">2.2.2 Surgical intervention</h6> <p>We included four studies with 454 participants (<a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]">Kang 2009</a>; <a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]">Liu 2013</a>; <a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]">Sakalis 2018</a>; <a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]">Yu 2010</a>). We are very uncertain about the effect of combination therapy on surgical intervention (RR 1.72, 95% CI 0.34 to 8.63; I² = 61%; <a href="./references#CD012336-fig-0012" title="">Analysis 2.5</a>); this corresponded to 71 more AUR (95% CI 77 fewer to 424 more) per 1000 participants treated with combination therapy. We rated the certainty of evidence as very low, downgrading for study limitations, inconsistency, and very serious imprecision. </p> </section> </section> <section id="CD012336-sec-0083"> <h5 class="title">2.3 Subgroup analysis</h5> <p>We were unable to perform any of the planned subgroup analysis due to a lack of relevant data. </p> </section> <section id="CD012336-sec-0084"> <h5 class="title">2.4 Sensitivity analysis</h5> <p>We perform the sensitive analysis by restricting the analysis by considering risk of bias, excluding studies with non‐blinded design. </p> <section id="CD012336-sec-0085"> <h6 class="title">2.4.1 Urologic symptom scores</h6> <p>We included six studies with 2308 participants (1484 men in combination therapy arm, 824 men in alpha‐blockers arm) (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). The MD for this sensitivity analysis was –2.62 (95% CI –5.83 to 0.58), which altered the treatment effect compared to the main analysis with a MD of –2.04 (95% CI –3.26 to –0.52). We rated the certainty of evidence as low, downgrading for inconsistency and imprecision. </p> </section> <section id="CD012336-sec-0086"> <h6 class="title">2.4.2 Quality of life</h6> <p>We included five studies with 1608 participants (960 men in combination therapy arm, 648 men in alpha‐blockers arm) (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]">Lee 2011</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]">Sener 2013</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>). The MD for this sensitivity analysis was –1.07 (95% CI –1.95 to –0.18), which did not alter the treatment effect compared to the main analysis with a MD of –0.71 (95% CI –1.03 to –0.38). We rated the certainty of evidence as low, downgrading for inconsistency and imprecision. </p> </section> <section id="CD012336-sec-0087"> <h6 class="title">2.4.3 Adverse events</h6> <p>We included five studies with 2732 participants (1714 men in combination therapy arm, 1018 men in alpha‐blockers arm) (<a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]">Cho 2017</a>; <a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]">Kaplan 2009</a>; <a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]">MacDiarmid 2008</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). The sensitivity analysis (RR 1.11, 95% CI 0.95 to 1.28) did not differ from the main analysis (RR 1.1, 95% CI 0.9 to 1.34). We rated the certainty of evidence as moderate, downgrading for imprecision. </p> </section> </section> </section> <section id="CD012336-sec-0088"> <h4 class="title">3. Combination therapy versus anticholinergics (short term)</h4> <p>We included three studies for this comparison (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). </p> <p>See <a href="./full#CD012336-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD012336-sec-0089"> <h5 class="title">3.1 Primary outcomes</h5> <section id="CD012336-sec-0090"> <h6 class="title">3.1.1 Urologic symptom scores</h6> <p>We included two studies with 710 participants (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). We are very uncertain about the effect of combination therapy on urologic symptom scores (MD –3.71, 95% CI –9.41 to 1.98; I² = 98%; <a href="./references#CD012336-fig-0013" title="">Analysis 3.1</a>). We rated the certainty of evidence as very low, downgrading for study limitations, inconsistency, and very serious imprecision. </p> </section> <section id="CD012336-sec-0091"> <h6 class="title">3.1.2 Quality of life</h6> <p>One study with 56 participants reported data for QoL (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>). Combination therapy may result in an improvement in QoL (MD –1.49, 95% CI –1.88 to –1.11; <a href="./references#CD012336-fig-0014" title="">Analysis 3.2</a>). We rated the certainty of evidence as low, downgrading for study limitations and imprecision. </p> </section> <section id="CD012336-sec-0092"> <h6 class="title">3.1.3 Adverse events</h6> <p>One studies with 661 participants reported data for adverse events (<a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). Combination therapy likely results in little to no difference in adverse events (RR 1.26, 95% CI 0.81 to 1.95; <a href="./references#CD012336-fig-0015" title="">Analysis 3.3</a>); this corresponded to 40 more adverse events (95% CI 29 fewer to 147 more) per 1000 participants treated with combination therapy. We rated the certainty of evidence as moderate, downgrading for imprecision. </p> </section> </section> <section id="CD012336-sec-0093"> <h5 class="title">3.2 Secondary outcomes</h5> <section id="CD012336-sec-0094"> <h6 class="title">3.2.1 Acute urinary retention</h6> <p>We included three studies with 1178 participants (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. ">Kaplan 2006</a>; <a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. ">Van Kerrebroeck 2013c</a>). Combination therapy may result in little to no difference in AUR (RR 0.55, 95% CI 0.11 to 2.65; I² = 0%; <a href="./references#CD012336-fig-0016" title="">Analysis 3.4</a>); this corresponded to 4 fewer AUR (95% CI 7 fewer to 13 more) per 1000 participants treated with combination therapy. We rated the certainty of evidence as low, downgrading for study limitations and imprecision. </p> </section> <section id="CD012336-sec-0095"> <h6 class="title">3.2.2 Surgical intervention</h6> <p>None of the studies reported data on number of men with a need of surgical intervention.</p> </section> </section> <section id="CD012336-sec-0096"> <h5 class="title">3.3 Subgroup analysis</h5> <p>We were unable to perform any of the planned secondary analyses due to a lack of relevant data. </p> </section> <section id="CD012336-sec-0097"> <h5 class="title">3.4 Sensitivity analysis</h5> <p>We rated all included studies at low risk of performance and detection bias, therefore the sensitivity analyses were identical with main analyses. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012336-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012336-sec-0098"></div> <section id="CD012336-sec-0099"> <h3 class="title" id="CD012336-sec-0099">Summary of main results</h3> <p>We included 23 studies in this review, involving 6285 men with LUTS/BPO and performed three comparisons (combination therapy with anticholinergics and alpha‐blockers versus placebo; combination therapy with anticholinergics and alpha‐blockers versus alpha‐blockers monotherapy; combination therapy with anticholinergics and alpha‐blockers versus anticholinergics monotherapy). </p> <section id="CD012336-sec-0100"> <h4 class="title">1. Combination therapy versus placebo</h4> <p>While combination therapy may have little or uncertain effects on urologic symptom scores and QoL, combination therapy likely increases the rate of adverse events. Using GRADE, we rated the certainty of evidence as very low to moderate. </p> </section> <section id="CD012336-sec-0101"> <h4 class="title">2. Combination therapy versus alpha‐blockers</h4> <p>Combination therapy had an uncertain effect on urologic symptom scores and QoL. Combination therapy appears not to have a significant effect on adverse events rate. Using GRADE, we rated the certainty of evidence as very low to low. </p> </section> <section id="CD012336-sec-0102"> <h4 class="title">3. Combination therapy versus anticholinergics</h4> <p>Combination therapy had an uncertain effect on urologic symptom scores, but may result in an improvement in QoL without additional adverse events. Using GRADE, we rated the certainty of evidence as very low to moderate. </p> </section> </section> <section id="CD012336-sec-0103"> <h3 class="title" id="CD012336-sec-0103">Overall completeness and applicability of evidence</h3> <p>Although many studies provide evidence for this review, several issues deserve consideration.</p> <p> <ul id="CD012336-list-0015"> <li> <p>The included studies were conducted worldwide including Asia, Europe, and the USA and about half of included studies were multi‐centered. However, most of participants in the studies to compare combination therapy to placebo, or anticholinergics were limiting applicability to men with different ethnic backgrounds. In addition, most included studies did not describe the baseline characteristics of the participants well in terms of race/ethnicity, body mass index, and prostate volume. </p> </li> <li> <p>The trials provided incomplete information on secondary outcomes; only one study reported AUR as an outcome and 19 studies only described it as one of the adverse events. Only two studies reported the number of participants receiving subsequent surgical interventions. Given the relatively high dropout rate with anticholinergics, more focused studies on the specific adverse events such as dry mouth, acute urinary retention, and the need of surgical intervention are needed. In addition, non‐randomized studies may be helpful to better understand the long‐term effectiveness and adverse events, but these were beyond the scope of this review. </p> </li> <li> <p>We were unable to perform any predefined subgroup analysis according to age, PSA, and severity of LUTS. To clarify the effects of combination therapy, we would need more studies for the population with different clinical settings to use our evidence directly. </p> </li> <li> <p>The body of evidence was limited to short‐term follow‐up of 12 months or less; most trials provided outcomes at 12 weeks. This appears insufficient to provide assurance of long‐term effectiveness and safety of combination therapy. More high‐quality studies with long‐term follow‐up are needed to address these limitations. </p> </li> </ul> </p> </section> <section id="CD012336-sec-0104"> <h3 class="title" id="CD012336-sec-0104">Quality of the evidence</h3> <p>We assessed the certainty of evidence using the GRADE approach and rated it as very low or low for most outcomes and comparisons. Our confidence in the estimates of effect were lowered for the following reasons. </p> <p> <ul id="CD012336-list-0016"> <li> <p>Study limitation: mainly issues surrounding allocation concealment and blinding.</p> </li> <li> <p>Inconsistency: high I² values reflecting clinically relevant heterogeneity, which we were unable to explain through secondary analyses. </p> </li> <li> <p>Imprecision: CIs that were wide and crossed assumed thresholds of clinically important differences. </p> </li> </ul> </p> </section> <section id="CD012336-sec-0105"> <h3 class="title" id="CD012336-sec-0105">Potential biases in the review process</h3> <p> <ul id="CD012336-list-0017"> <li> <p>While we performed a comprehensive literature search including trial registries and grey literatures for unpublished, planned, or ongoing studies without restrictions on language of publication or publication status, we should consider the presence of unpublished data with non‐statistical results (e.g. time lag bias). </p> </li> <li> <p>We tried to contact study authors to obtain additional information on several occasions. However, we received feedback only from three authors (<a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a>; <a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]">Nishizawa 2011</a>; <a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]">Van Kerrebroeck 2013b</a>). This may represent a source of bias with potential under‐reporting. </p> </li> <li> <p>To minimize variability between participants, we performed data analysis based on mean changes from baseline. For some included studies that did not report mean changes and SDs, we calculated those values. However, calculation of changes may result in risks of increased measurement error. </p> </li> </ul> </p> </section> <section id="CD012336-sec-0106"> <h3 class="title" id="CD012336-sec-0106">Agreements and disagreements with other studies or reviews</h3> <p>We identified three systematic reviews assessing the efficacy and safety of combination therapy with alpha‐blockers and anticholinergics for men with LUTS/BPO (<a href="./references#CD012336-bbs2-0061" title="FilsonCP , HollingsworthJM , ClemensJQ , WeiJT . The efficacy and safety of combined therapy with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. Journal of Urology2013;190(6):2153-60. [PMID: 23727412]">Filson 2013</a>; <a href="./references#CD012336-bbs2-0076" title="KimHJ , SunHY , ChoiH , ParkJY , BaeJH , DooSW , et al. Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis. PloS One2017;12(1):e0169248. [PMID: 28072862]">Kim 2017</a>; <a href="./references#CD012336-bbs2-0103" title="XinZ , HuangY , LuJ , ZhangQ , ChenC . Addition of antimuscarinics to alpha-blockers for treatment of lower urinary tract symptoms in men: a meta-analysis. Urology2013;82(2):270-7. [PMID: 23896090]">Xin 2013</a>). The result from <a href="./references#CD012336-bbs2-0061" title="FilsonCP , HollingsworthJM , ClemensJQ , WeiJT . The efficacy and safety of combined therapy with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. Journal of Urology2013;190(6):2153-60. [PMID: 23727412]">Filson 2013</a> showed that combination therapy resulted in a significant improvement in IPSS storage sub‐score and urinary frequency, without increased risk of AUR compared to alpha‐blockers alone. Another review also found that combination therapy was associated with an significant improvement in total IPSS, IPSS storage sub‐score, QoL, urgency, and frequency compared to alpha‐blockers (<a href="./references#CD012336-bbs2-0103" title="XinZ , HuangY , LuJ , ZhangQ , ChenC . Addition of antimuscarinics to alpha-blockers for treatment of lower urinary tract symptoms in men: a meta-analysis. Urology2013;82(2):270-7. [PMID: 23896090]">Xin 2013</a>). By contrast, our review used overall IPSS as a primary outcome and found that combination therapy had a similar or uncertain effect on IPSS compared to alpha‐blockers. Similar to our finding, <a href="./references#CD012336-bbs2-0076" title="KimHJ , SunHY , ChoiH , ParkJY , BaeJH , DooSW , et al. Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis. PloS One2017;12(1):e0169248. [PMID: 28072862]">Kim 2017</a> showed that combination therapy did not result in clinically important improvements in urologic symptoms, QoL, and acute urinary retention rate compared to alpha‐blockers. The potential reason for the contradictory finding between previously published reviews and ours may result from the difference in included studies. <a href="./references#CD012336-bbs2-0061" title="FilsonCP , HollingsworthJM , ClemensJQ , WeiJT . The efficacy and safety of combined therapy with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. Journal of Urology2013;190(6):2153-60. [PMID: 23727412]">Filson 2013</a> only included placebo‐controlled RCTs and <a href="./references#CD012336-bbs2-0103" title="XinZ , HuangY , LuJ , ZhangQ , ChenC . Addition of antimuscarinics to alpha-blockers for treatment of lower urinary tract symptoms in men: a meta-analysis. Urology2013;82(2):270-7. [PMID: 23896090]">Xin 2013</a> included quasi‐randomized studies as well. In addition, our review only included studies with at least 12 weeks of follow‐up and interpreted the study results using thresholds of minimal clinical important differences. Our interpretation is also more critical as we use GRADE including the domains of imprecision to rate the certainty of evidence which led us to rate many results as very uncertain.  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012336-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012336-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD012336-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD012336-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combination therapy versus placebo (short term), Outcome 1: Urologic symptom scores" data-id="CD012336-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Combination therapy versus placebo (short term), Outcome 1: Urologic symptom scores </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combination therapy versus placebo (short term), Outcome 2: Quality of life" data-id="CD012336-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Combination therapy versus placebo (short term), Outcome 2: Quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combination therapy versus placebo (short term), Outcome 3: Adverse events" data-id="CD012336-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Combination therapy versus placebo (short term), Outcome 3: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combination therapy versus placebo (short term), Outcome 4: Acute urinary retention" data-id="CD012336-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Combination therapy versus placebo (short term), Outcome 4: Acute urinary retention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combination therapy versus alpha‐blockers (short term), Outcome 1: Urologic symptom scores" data-id="CD012336-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Combination therapy versus alpha‐blockers (short term), Outcome 1: Urologic symptom scores </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combination therapy versus alpha‐blockers (short term), Outcome 2: Quality of life" data-id="CD012336-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Combination therapy versus alpha‐blockers (short term), Outcome 2: Quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combination therapy versus alpha‐blockers (short term), Outcome 3: Adverse events" data-id="CD012336-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Combination therapy versus alpha‐blockers (short term), Outcome 3: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combination therapy versus alpha‐blockers (short term), Outcome 4: Acute urinary retention" data-id="CD012336-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Combination therapy versus alpha‐blockers (short term), Outcome 4: Acute urinary retention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combination therapy versus alpha‐blockers (short term), Outcome 5: Surgical intervention" data-id="CD012336-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Combination therapy versus alpha‐blockers (short term), Outcome 5: Surgical intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Combination therapy versus anticholinergics (short term), Outcome 1: Urologic symptom scores" data-id="CD012336-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Combination therapy versus anticholinergics (short term), Outcome 1: Urologic symptom scores </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Combination therapy versus anticholinergics (short term), Outcome 2: Quality of life" data-id="CD012336-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Combination therapy versus anticholinergics (short term), Outcome 2: Quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Combination therapy versus anticholinergics (short term), Outcome 3: Adverse events" data-id="CD012336-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Combination therapy versus anticholinergics (short term), Outcome 3: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012336-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/urn:x-wiley:14651858:media:CD012336:CD012336-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Combination therapy versus anticholinergics (short term), Outcome 4: Acute urinary retention" data-id="CD012336-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_t/tCD012336-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Combination therapy versus anticholinergics (short term), Outcome 4: Acute urinary retention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/media/CDSR/CD012336/image_n/nCD012336-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012336-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Combination therapy versus placebo for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Combination therapy versus placebo for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with lower urinary tract symptoms related to benign prostatic obstruction<br/><b>Setting:</b> multi‐center/outpatients/China, USA, Europe<br/><b>Intervention:</b> combination therapy<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo (short term)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with combination therapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urologic symptom scores</b><br/>assessed with: IPSS<br/>Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/>Follow‐up: range 12–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1792<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of urologic symptom scores ranged from –7.2 to –5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 2.73 lower</b><br/>(5.55 lower to 0.08 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b><br/>assessed with: IPSS‐QoL<br/>Scale from: 0 (delighted) to 6 (terrible)<br/>Follow‐up: range 12–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>991<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of QoL ranged from –1.6 to –0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.97 lower</b><br/>(2.11 lower to 0.16 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1848<br/>(3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.24</b><br/>(1.04 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 more per 1000<br/>(10 more to 119 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>AUR</b><br/>Follow‐up: range 12–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2369<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.94</b><br/>(0.41 to 9.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Surgical intervention</b> – not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AUR:</b> acute urinary retention; <b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: unclear or high risk of bias in one or more domain for selection, attrition, or reporting bias in half or more included studies.<br/><sup>b</sup>Not downgraded for inconsistency despite substantial or considerable heterogeneity: study limitations of <a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]">Cai 2016</a> may cause inconsistency.<br/><sup>c</sup>Downgraded one level for inconsistency: substantial or considerable heterogeneity.<br/><sup>d</sup>Downgraded one level for imprecision: confidence interval crossed assumed threshold of clinically important difference.<br/><sup>e</sup>Downgraded two levels for imprecision: wide confidence interval crossed assumed threshold of clinically important difference and very rare event.<br/><sup>f</sup>No event in control group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Combination therapy versus placebo for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012336-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Combination therapy versus alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Combination therapy versus alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with lower urinary tract symptoms related to benign prostatic obstruction<br/><b>Setting:</b> outpatients/Asia, USA, Europe<br/><b>Intervention:</b> combination therapy<br/><b>Comparison:</b> alpha‐blockers </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with alpha‐blockers (short term)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with combination therapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urologic symptom scores</b><br/>assessed with: IPSS<br/>Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/>Follow‐up: range 12 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3631<br/>(19 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of urologic symptom scores ranged from –11.9 to –2.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 2.04 lower</b><br/>(3.56 lower to 0.52 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b><br/>assessed with: IPSS‐QoL<br/>Scale from: 0 (delighted) to 6 (terrible)<br/>Follow‐up: range 12 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2687<br/>(15 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of QoL ranged from –2.9 to 0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.71 lower</b><br/>(1.03 lower to 0.38 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>Follow‐up: range 12 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3561<br/>(12 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.10</b><br/>(0.90 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 more per 1000<br/>(23 fewer to 78 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>AUR</b><br/>Follow‐up: range 12 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4669<br/>(19 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.03</b><br/>(0.97 to 4.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000<br/>(0 to 12 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Surgical intervention</b><br/>Follow‐up: range 12–26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>454<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>d</sup><sup>,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.72</b><br/>(0.34 to 8.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 more per 1000<br/>(77 fewer to 424 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AUR:</b> acute urinary retention; <b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>QoL:</b> quality of life. <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: unclear or high risk of bias in one or more domain in half or more included studies.<br/><sup>b</sup>Downgraded one level for imprecision: confidence interval crossed assumed threshold of clinically important difference.<br/><sup>c</sup>Downgraded one level for inconsistency: substantial or considerable heterogeneity.<br/><sup>d</sup>Downgraded one level for study limitations: unclear or high risk of selection, performance, detection, reporting bias.<br/><sup>e</sup>Downgraded two levels for imprecision: wide confidence interval crossed assumed threshold of clinically important difference and very rare event.<br/><sup>f</sup>No event in control group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Combination therapy versus alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012336-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Combination therapy versus anticholinergics for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Combination therapy versus anticholinergics for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with lower urinary tract symptoms related to benign prostatic obstruction<br/><b>Setting:</b> multi‐center/outpatients/China, USA, Europe<br/><b>Intervention:</b> combination therapy<br/><b>Comparison:</b> anticholinergics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with anticholinergics (short term)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with combination therapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urologic symptom scores</b><br/>assessed with: IPSS<br/>Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/>Follow‐up: range 12–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>710<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of urologic symptom scores ranged from –6.5 to –5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 3.71 lower</b><br/>(9.41 lower to 1.98 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b><br/>assessed with: IPSS‐QoL<br/>Scale from: 0 (delighted) to 6 (terrible)<br/>Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change of QoL was –1.41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.49 lower</b><br/>(1.88 lower to 1.11 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>661<br/>(1 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.26</b><br/>(0.81 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 more per 1000<br/>(29 fewer to 147 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>AUR</b><br/>Follow‐up: range 12–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1178<br/>(3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.55</b><br/>(0.11 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 fewer per 1000<br/>(7 fewer to 13 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Surgical intervention</b> – not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AUR:</b> acute urinary retention; <b>CI:</b> confidence interval; <b>IPSS:</b> International Prostate Symptom Score; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: unclear or high risk of bias in one or more domain for selection, attrition, or reporting bias.<br/><sup>b</sup>Downgraded one level for inconsistency: substantial or considerable heterogeneity.<br/><sup>c</sup>Downgraded one level for imprecision: confidence interval crossed assumed threshold of clinically important difference.<br/><sup>d</sup>Downgraded one level for imprecision: insufficient information size.<br/><sup>e</sup>Wide confidence interval in relative effect, but small risk difference in absolute effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Combination therapy versus anticholinergics for treating lower urinary tract symptoms related to benign prostatic obstruction (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012336-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of intervention (duration of follow‐up)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Description of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial period</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Ethnic groups (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of disease</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="4" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]"><b>Cai 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + tolterodine ER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>24 weeks (24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Men ages ≥ 50 yr; IPSS ≥ 12; QoL score ≥ 3; TPV ≥ 25 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>December 2009 to March 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>100% Chinese</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: tolterodine ER + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: placebo + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]"><b>Cho 2017</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: alfuzosin + imidafenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 45 yr; with LUTS and storage symptoms for &gt; 3 months; IPSS ≥ 12; IPSS question 4 score ≥ 2; TPV &gt; 20 mL; micturitions ≥ 8 per 24 h; 5 mL/s ≤ Qmax ≤ 15 mL/s </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: alfuzosin + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]"><b>He 2012</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 50 yr; IPSS ≥ 8; QoL score ≥ 3; OABSS ≥ 3; Qmax &lt; 15 mL/s; PRV &lt; 60 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>June 2010 to December 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]"><b>Kang 2009</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 50 yr; IPSS ≥ 12; QoL score ≥ 3; TPV ≥ 25 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>May 2007 to April 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="4" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. "><b>Kaplan 2006</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + tolterodine ER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Men ages ≥ 40 yr; IPSS ≥ 12; QoL score ≥ 3; micturition frequency ≥ 8 per 24 h and urgency ≥ 3 per 24 h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>November 2004 to May 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>82.5% white and 17.5% non‐white (black, Asian, other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: tolterodine ER + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: placebo + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]"><b>Kaplan 2009</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 13; PPBC ≥ 3; Qmax ≥ 5 mL/s with volume ≤ 200 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>May 2006 to January 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>83.4% white and 16.6% non‐white (black, other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]"><b>Kaplan 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin OCAS 0.4 mg + solifenacin 6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 8; Bladder Outlet Obstruction Index ≥ 20; Qmax ≤ 12 mL/s with volume ≥ 120 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>June 2007 to August 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>96.4% white and 3.6% non‐white (black, Asian, other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin OCAS 0.4 mg + solifenacin 9 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]"><b>Lee 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: doxazosin GITS + tolterodine ER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 14 (voiding subscore ≥ 8 and storage subscore ≥ 6); QoL ≥ 3; micturition frequency ≥ 8 per 24 h; urgency ≥ 1 per 24 h; TPV ≥ 20 mL; Qmax ≤ 15 mL/s with volume ≥ 125 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: doxazosin GITS + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]"><b>Lee 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin 0.2 mg + solifenacin 5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 8; OABSS ≥ 3; Question 2 of OABSS ≥ 2; TPV ≥ 20 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin 0.2 mg + solifenacin 10 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]"><b>Liu 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages &gt; 50 yr; IPSS &gt; 8; OABSS &gt; 3; Qmax &lt; 5 mL/s; micturition ≥ 8; nocturia ≥ 3 per 24 h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]"><b>MacDiarmid 2008</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin + oxybutynin ER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 13 and storage IPSS ≥ 8; Qmax ≥ 8 mL/s with volume ≥ 125 mL; PVR ≤ 150 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>March 2004 to June 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]"><b>Matsukawa 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: silodosin + propiverine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 year (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 50 yr; IPSS ≥ 8; QoL score ≥ 3; OABSS ≥ 3; urinary urgency episodes ≥ 1 per week; TPV ≥ 25 mL; Qmax &lt; 15 mL/s with volume ≥ 100 mL; PVR &lt; 150 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>August 2011 and June 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: silodosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]"><b>Memon 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: alfuzosin + tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 40 yr; IPSS 15–30; Qmax &lt; 5 mL/s with volume ≥ 100 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>May 2012 and September 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: alfuzosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]"><b>Nishizawa 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin 0.2 mg + propiverine 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Men ages ≥ 50 yr; IPSS ≥ 8 with urgency item score ≥ 1; QoL ≥ 2; Qmax &lt; 15 mL/s with volume ≥ 150 mL; 8 micturitions and 1 urgency per 24 h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>October 2004 to September 2008.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin 0.2 mg + propiverine 20 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin, daily</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]"><b>Sakalis 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin OCAS + solifenacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26 weeks (26 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 50 yr; IPSS storage subscore ≥ voiding subscore and score ≥ 3 in the IPSS urgency question; ≥ 3 urgency episodes per 24 h; prostate volume ≥ 30 mL; Qmax ≥ 10 mL/s; PVR ≤ 100 mL; PSA ≤ 4 ng/mL. Participants with suspicious rectal exam or PSA values 4–10 ng/mL (or both) were included only after negative prostate biopsy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>October 2013 to June 2015.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Greece</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100% white</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin OCAS</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]"><b>Sener 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: propiverine + terazosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 year (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 40 yr; IPSS &gt; 12; micturition frequency &gt; 8 per 24 h; urgency episodes &gt; 3 per 24 h; PSA &lt; 2.5 ng/mL; having documented detrusor pressure &gt; 10 cmH<sub>2</sub>O in urodynamic studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>May 2009 to November 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo + terazosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]"><b>Shen 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: terazosin+ tolterodine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 60 yr; IPSS ≥ 8; TPV &lt; 60 mL; Qmax &lt; 15 mL/s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>January 2010 to October 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: terazosin</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="4" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]"><b>Van Kerrebroeck 2013b</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin OCAS 0.4 mg + solifenacin 6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 13; Qmax 4–12 mL/s with volume ≥ 120 mL; micturition frequency ≥ 8 per 24 h; urgency episodes ≥ 2 per 24 h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>January 2010 to March 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>99.2% white and 0.8% non‐white (black, Asian, other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin OCAS 0.4 mg + solifenacin 9 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin OCAS + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: placebo + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="8" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. "><b>Van Kerrebroeck 2013c</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: solifenacin 3 mg + tamsulosin OCAS 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>Men ages ≥ 45 yr; IPSS ≥ 13; Qmax 4–15 mL/s with volume ≥ 120 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>Multi‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>99.6% white and 0.4% non‐white (black, other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: solifenacin 6 mg + tamsulosin OCAS 0.4 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: solifenacin 9 mg + tamsulosin OCAS 0.4 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: solifenacin 3 mg + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: solifenacin 6 mg + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C4: solifenacin 9 mg + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C5: tamsulosin OCAS 0.4 mg + placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]"><b>Wang 2015</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin 0.2 mg + fesoterodine 4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 50 yr; IPSS &gt; 8 and storage IPSS ≥ 6; QoL score ≥ 3; Qmax &lt; 15 mL/s with volume ≥ 200 mL; PRV &lt; 60 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>January 2013 to September 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin 0.2 mg</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]"><b>Wang 2017</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin 0.2 mg + solifenacin 5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men; IPSS ≥ 8; OABSS ≥ 3; mean urination frequency ≥ 8 times/day; nocturia episodes ≥ 2; urine volume ≥ 200 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>April 2014 to December 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin 0.2 mg</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]"><b>Wu 2009</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin 0.2 mg + tolterodine 2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages &gt; 50 yr; IPSS &gt; 8 and storage IPSS ≥ 6; QoL score ≥ 3; Qmax &lt; 15 mL/s with volume ≥ 200 mL; PRV &lt; 60 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>June 2006 to June 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin 0.2 mg</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]"><b>Yu 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: doxazosin 4 mg + tolterodine 2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks (12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men ages ≥ 50 yr; IPSS ≥ 12; QoL score ≥ 3; complain of urgency and frequency with volume &lt; 300 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>October 2007 to December 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single‐center/outpatients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: doxazosin 4 mg</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>— denotes not reported.</p> <p>C: comparator; I: intervention; ER: extended release; GITS: gastrointestinal therapeutic system; h: hour; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; OABSS: Overactive Bladder Symptom Score; OCAS: oral controlled absorption system; PPBC: Patient Perception of Bladder Condition; PRV: postvoid residual; Qmax: maximum flow rate; QoL: quality of life; s: second; SD: standard deviation; TPV: total prostate volume; yr: year. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012336-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Description of Interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) (route, frequency, total dose/day)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) appropriate as applied in a clinical practice setting<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator(s) (route, frequency, total dose/day)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator(s) appropriate as applied in a clinical practice setting<sup>a</sup> </b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0001" title="CaiJL , ZhouZ , YangY , YanYF , JingS , NaYQ . Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chinese Medical Journal2016;129(24):2899-906. [DOI: 10.4103/0366-6999.195461]"><b>Cai 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + tolterodine ER (orally, once a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; tolterodine ER 4 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; tolterodine ER, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: tolterodine ER (orally, once a day, total 4 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tolterodine ER 4 mg, orally, once a day</p> <p>Provision for contraindications: tolterodine ER, closed‐angle glaucoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: placebo + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/CPS</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0002" title="ChoS , HoonC , ParkJY , BaeJH , LeeKW , YooTK , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. European Urology, Supplements2017;16(3):e933. [DOI: 10.1016/S1569-9056(17)30597-3]ChoS , KwonSS , LeeKW , YooTK , ShinDG , KimSW , et al. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice2017;71(5):e12938. [DOI: 10.1111/ijcp.12938]"><b>Cho 2017</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: alfuzosin (orally, once a day, total 10 mg/day) + imidafenacin (orally, twice a day, total 0.2 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: alfuzosin 10 mg, orally, once a day; imidafenacin 0.1 mg, orally, twice a day, </p> <p>Provision for contraindications: alfuzosin, postural hypotension; imidafenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: alfuzosin (orally, once a day, total 10 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: alfuzosin 10 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0003" title="HeXY , ZhangYG , YangQ . Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder [坦索罗辛联合索利那新治疗良性前列腺增生伴膀胱过度活动症]. Practical Pharmacy and Clinical Remedies2012;15(12):806-7. [DOI: 10.14053/j.cnki.ppcr.2012.12.029]"><b>He 2012</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + solifenacin (orally, once a day, total 5 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0004" title="KangIS , SungZH , JongBL . The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms. Korean Journal of Urology2009;50(11):1078-82. [DOI: 10.4111/kju.2009.50.11.1078]"><b>Kang 2009</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + propiverine (orally, once a day, total 10 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; propiverine 20 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; propiverine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0005" title="KaplanSA , RoehrbornCG , ChancellorM , CarlssonM , BavendamT , GuanZ . Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU international2008;102(9):1133-9. KaplanSA , RoehrbornCG , RovnerES , CarlssonM , BavendamT , GuanZ . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Journal of the American Medical Association2006;296(19):2319-28. [DOI: 10.1001/jama.296.19.2319]RoehrbornCG , KaplanSA , JonesJS , WangJT , BavendamT , GuanZH . Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. European Urology2009;55(2):472-81. "><b>Kaplan 2006</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.4 mg/day) + tolterodine ER (orally, once a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; tolterodine ER 4 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; tolterodine ER, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.4 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: tolterodine ER (orally, once a day, total 4 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tolterodine ER 4 mg, orally, once a day</p> <p>Provision for contraindications: tolterodine ER, closed‐angle glaucoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: placebo + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/CPS</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0006" title="KaplanSA , McCammonK , FincherR , FakhouryA , HeWZ . Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Journal of Urology2009;182(6):2825-30. [DOI: 10.1016/j.juro.2009.08.023]"><b>Kaplan 2009</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.4 mg/day) + solifenacin (orally, once a day, total 5 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.5 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0007" title="KaplanSA , HeW , KoltunWD , CummingsJ , SchneiderT , FakhouryA . Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. European Urology2013;63(1):158-65. [DOI: 10.1016/j.eururo.2012.07.003]"><b>Kaplan 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin OCAS and solifenacin 6 mg (orally, once a day, total tamsulosin 0.4 mg/day and solifenacin 6 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin OCAS and solifenacin 6 mg (orally, once a day, total tamsulosin 0.4 mg/day and solifenacin 9 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0008" title="LeeSH , ChungBH , KimSJ , KimJH , KimJC , LeeJY . Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer and Prostatic Diseases2011;14(4):320-5. [DOI: 10.1038/pcan.2011.22]"><b>Lee 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: doxazosin GITS (orally, once a day, total doxazosin 4 mg/day) + tolterodine ER (orally, once a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: doxazosin 4 mg, orally, once a day; tolterodine ER 4 mg, orally, once a day </p> <p>Provision for contraindications: doxazosin, postural hypotension; tolterodine ER, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: doxazosin gastrointestinal therapeutic system (GITS) (orally, once a day, total doxazosin 4 mg/day) + placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: doxazosin 4 mg, orally, once a day</p> <p>Provision for contraindications: doxazosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0009" title="LeeKW , HurKJ , KimSH , ChoSY , BaeSR , ParkBH , et al. Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study. Lower Urinary Tract Symptoms2016;9(3):129-33. [DOI: 10.1111/luts.12124]"><b>Lee 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + solifenacin (orally, once a day, total 5 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin (orally, once a day, total 0.2 mg/day) + solifenacin (orally, once a day, total 10 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0010" title="LiuS , YuK , LiF , YuZH , YangZX , XiaZY . Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder [索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻]. Journal of Chongqing Medical University2013;38(3):330-2. [DOI: 10.11699/cyxb20130326]"><b>Liu 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + solifenacin (orally, once a day, total 5 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0011" title="MacDiarmidSA , PetersKM , ChenA , ArmstrongRB , OrmanC , AquilinaJW , et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clinic Proceedings2008;83(9):1002-10. [DOI: 10.4065/83.9.1002.]"><b>MacDiarmid 2008</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.4 mg/day) + oxybutynin ER (orally, once a day, total 10 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; oxybutynin ER 10 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; oxybutynin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (0.4 mg, once a day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0012" title="MatsukawaY , FunahashiY , MatsuoK , IshidaS , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. Journal of Urology2016;195(4):e465-6. MatsukawaY , TakaiS , FujitaT , MajimaT , KatoM , YamamotoT , et al. Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study. European Urology, Supplements2016;15(3):e867+e867a. MatsukawaY , TakaiS , FunahashiY , KatoM , YamamotoT , GotohM . Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourology and Urodynamics2016;36(3):748-54. [DOI: 10.1002/nau.23013]"><b>Matsukawa 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: silodosin (orally, once a day, total 8 mg/day) + propiverine (orally, once a day, total 20 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: silodosin 8 mg, orally, once a day; propiverine 20 mg, orally, once a day </p> <p>Provision for contraindications: silodosin, postural hypotension; propiverine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: silodosin (orally, once a day, total 8 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: silodosin 8 mg, orally, once a day</p> <p>Provision for contraindications: silodosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0013" title="MemonI , AbdullahA , PirzadaA , JavedA , SheikhS , AghaG , et al. Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial. Urology2013;82(3 Suppl 1):S78. MemonI , JavedA , PirzadaAJ , AbdullahA , AliS , AhmedSF . Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms. Rawal Medical Journal2014;39(4):421-4. [EMBASE: 2014928955]"><b>Memon 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: alfuzosin (orally, once a day, total 10 mg/day) + tolterodine (orally, 2 mg twice a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: alfuzosin 10 mg, orally, once a day; tolterodine 2 mg, orally, twice a day </p> <p>Provision for contraindications: alfuzosin, postural hypotension; tolterodine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: alfuzosin 10 mg, once a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: alfuzosin 10 mg, orally, once a day</p> <p>Provision for contraindications: alfuzosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0014" title="NishizawaO , YamaguchiO , TakedaM , YokoyamaO . Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Lower Urinary Tract Symptoms2011;3(1):29-35. [DOI: 10.1111/j.1757-5672.2010.00081.x]"><b>Nishizawa 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin 0.2 mg (orally, once a day, total 0.2 mg/day) + propiverine (orally, once a day, total 10 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; propiverine 20 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; propiverine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>C1: tamsulosin 0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin 0.2 mg (orally, once a day, total 0.2 mg/day) + propiverine (orally, once a day, total 20 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; propiverine 20 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; propiverine, closed‐angle glaucoma </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0015" title="SakalisV , SfiggasV , VourosI , SalpiggidisG , PapathanasiouA , ApostolidisA . Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. International Journal of Urology2018;25(8):737-45. [DOI: 10.1111/iju.13721]"><b>Sakalis 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin OCAS (orally, once a day, total 0.4 mg/day) and solifenacin (orally, once a day, total 5 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin oral controlled absorption system (TOCAS) (orally, once a day, total 0.4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0016" title="SenerNC , OzturkU , GoktugHN , GucukA , NalbantI , YesilS , et al. Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity. International Brazilian Journal of Urology2013;39(4):513-8. [DOI: 10.1590/S1677-5538.IBJU.2013.04.09]"><b>Sener 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: terazosin 2 mg (orally, once a day, total 2 mg/day) + propiverine (orally, once a day, total 15 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: terazosin 2 mg, orally, once a day; propiverine 20 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; propiverine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: terazosin (orally, once a day, total 2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: terazosin 2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0017" title="ShenJ , ChenJH , YuQW , ShenJ , SunP . Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia [特拉唑嗪与托特罗定联合治疗良性前列腺增生的疗效评估]. Journal of Shanghai Jiaotong University (Medical Science)2011;31(6):809-12. [DOI: 10.3969/j.issn.1674-8115.2011.06.028]"><b>Shen 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: terazosin 2 mg (orally, once a day, total 2 mg/day) + tolterodine (orally, 2 mg twice a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: terazosin 2 mg, orally, once a day; tolterodine 2 mg, orally, twice a day </p> <p>Provision for contraindications: terazosin, postural hypotension; tolterodine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: terazosin (orally, once a day, total 2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: terazosin 2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0018" title="DrakeM , SpeakmanM , KerrebroeckP , DrogendijkT , KlaverM . Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial. Urology2011;78(3 Suppl 1):S58. [DOI: doi.org/10.1016/j.urology.2011.07.099]Van KerrebroeckP , ChappleC , DrogendijkT , KlaverM , SokolR , SpeakmanM , et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology2013;64(6):1003-12. [DOI: 10.1016/j.eururo.2013.07.034]"><b>Van Kerrebroeck 2013b</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin OCAS (orally, once a day, total 0.4 mg/day) and solifenacin (orally, once a day, total 6 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin oral controlled absorption system (TOCAS) (orally, once a day, total 0.4 mg/day) + placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: tamsulosin OCAS (orally, once a day, total 0.4 mg/day) and solifenacin (orally, once a day, total 9 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: placebo + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/CPS</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="5" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0019" title="HaabF , Van KerrebroeckP , KleckaJ , VikV , AnguloJ , Garcia-HernandezA , et al. Safety of tamsulosin OCAS™ plus solifenacin in men with LUTS associated with BPH in the SATURN trial. Urology2011;78(3):S264-5. KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3 Suppl 1):S58-s59. KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV . Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial (Abstract number 327). European Urology, Supplements2011;10(2):120. [DOI: 10.1016/S1569-9056(11)60323-0]Van KerrebroeckP , HaabF , AnguloJC , VikV , KatonaF , Garcia-HernandezA , et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). European Urology2013;64(3):398-407. [DOI: 10.1016/j.eururo.2013.03.031]Van KerrebroeckP , KrhutJ , LiehneJ , GombergV , Cambronero SantosJ , Garcia-HernandezA , et al. The effects of tamsulosin OCAS™ plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial. Urology2011;78(3):S58-9. Van KerrebroeckP , OelkeM , KatonaF , Garcia-HernandezA , KlaverM . Efficacy of tamsulosin OCAS™ plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN). Urology2010;76(3):S12-3. Van KerrebroeckPE , OelkeM , KatonaF , KrhutJ , LiehneJ , GombergV , et al. Effects of tamsulosin OCAS™ and solifenacin on efficacy and QoL parameters in men with LUTS/BPH in the SATURN trial. European Urology, Supplements2011;10(2):120. WyndaeleJ , CicaleseAR , JzermanWI , SokolR , HechelmannW , Garcia-HernandezA , et al. Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial. Urology2011;78(3 Suppl 1):S58. "><b>Van Kerrebroeck 2013c</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: solifenacin (orally, once a day, total 3 mg/day) + tamsulosin OCAS (orally, once a day, total 0.4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: solifenacin (orally, once a day, total 6 mg/day) + tamsulosin OCAS (orally, once a day, total 0.4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: solifenacin (orally, once a day, total 3 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: solifenacin 5 mg, orally, once a day</p> <p>Provision for contraindications: solifenacin, closed‐angle glaucoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I3: solifenacin (orally, once a day, total 9 mg/day) + tamsulosin OCAS (orally, once a day, total 0.4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C3: solifenacin (orally, once a day, total 6 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: solifenacin 5 mg, orally, once a day</p> <p>Provision for contraindications: solifenacin, closed‐angle glaucoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C4: solifenacin (orally, once a day, total 9 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: solifenacin 5 mg, orally, once a day</p> <p>Provision for contraindications: solifenacin, closed‐angle glaucoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C5: tamsulosin OCAS (orally, once a day, total 0.4 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0020" title="WangZH , LiuSQ , DuLH . Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder [大剂量坦索罗辛联合富马酸非索罗定治疗良性前列腺增生伴膀胱活动过度的疗效]. China Journal of Modern Medicine2015;25(34):27-30. [1005-8982(2015)34-0027-04]"><b>Wang 2015</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + fesoterodine (orally, once a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; fesoterodine 4 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; fesoterodine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0021" title="WangH , ChangY , LiangH . Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pakistan Journal of Medical Sciences2017;33(4):988-92. [DOI: 10.12669/pjms.334.12757]"><b>Wang 2017</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + solifenacin (orally, once a day, total 5 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; solifenacin 5 mg, orally, once a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; solifenacin, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0022" title="WuZL , GengH . Combination of tolterodine and tamsulosin for benign prostatic hyperplasia [托特罗定和坦索罗辛联合治疗良性前列腺增生]. Zhonghua Nan Ke Xue [National Journal of Andrology]2009;15(7):639-41. [1009-3591(2009)07-0639-03]"><b>Wu 2009</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tamsulosin (orally, once a day, total 0.2 mg/day) + tolterodine (orally, 2 mg once a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day; tolterodine 2 mg, orally, twice a day </p> <p>Provision for contraindications: tamsulosin, postural hypotension; tolterodine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: tamsulosin (orally, once a day, total 0.2 mg/day) + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: tamsulosin 0.2 mg, orally, once a day</p> <p>Provision for contraindications: tamsulosin, postural hypotension</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012336-bbs2-0023" title="YuZ , XiaoYH , SunXY , HeJ , ZengDS . Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder [多沙唑嗪联合托特罗定治疗前列腺增生合并膀胱过度活动症的疗效分析]. Sichuan Medical Journal2010;31(12):1780-2. [DOI: 10.16252/j.cnki.issn1004-0501-2010.12.036]"><b>Yu 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: doxazosin (orally, once a day, total doxazosin 4 mg/day) + tolterodine (orally, 2 mg twice a day, total 4 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: doxazosin 4 mg, orally, once a day; tolterodine 2 mg, orally, twice a day </p> <p>Provision for contraindications: doxazosin, postural hypotension; tolterodine, closed‐angle glaucoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: doxazosin (orally, once a day, total doxazosin 4 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dosing scheme: doxazosin 4 mg, orally, once a day</p> <p>Provision for contraindications: doxazosin, postural hypotension</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>The term 'clinical practice setting' refers to the specification of the intervention/comparator as used in the course of a standard medical treatment (such as dose, dose escalation, dosing scheme, provision for contraindications, and other important features). </p> <p>C: comparator; I: intervention; N/CPS: no specification of clinical practice setting possible; ER: extended release; GITS: gastrointestinal therapeutic system; OCAS: oral controlled absorption system. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Description of Interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/full#CD012336-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012336-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Combination therapy versus placebo (short term)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Urologic symptom scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.73 [‐5.55, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐2.11, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.04, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Acute urinary retention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.41, 9.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Combination therapy versus placebo (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012336-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Combination therapy versus alpha‐blockers (short term)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Urologic symptom scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.04 [‐3.56, ‐0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.03, ‐0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.90, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Acute urinary retention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [0.97, 4.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Surgical intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.34, 8.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Combination therapy versus alpha‐blockers (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012336-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Combination therapy versus anticholinergics (short term)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Urologic symptom scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.71 [‐9.41, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.49 [‐1.88, ‐1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.81, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Acute urinary retention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.11, 2.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Combination therapy versus anticholinergics (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012336.pub2/references#CD012336-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012336.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012336-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012336-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012336-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012336-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD012336-note-0013">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012336-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012336-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012336-note-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012336-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012336\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012336\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012336\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012336\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012336\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012336.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012336.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012336.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012336.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012336.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728950724"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012336.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728950727"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012336.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed0fe394e9368',t:'MTc0MDcyODk1MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 